US20180263975A1 - Methods Of Treating Motor And Movement Disorders And Side Effects Thereof Associated with Parkinson's Disease Treatments - Google Patents
Methods Of Treating Motor And Movement Disorders And Side Effects Thereof Associated with Parkinson's Disease Treatments Download PDFInfo
- Publication number
- US20180263975A1 US20180263975A1 US15/542,286 US201615542286A US2018263975A1 US 20180263975 A1 US20180263975 A1 US 20180263975A1 US 201615542286 A US201615542286 A US 201615542286A US 2018263975 A1 US2018263975 A1 US 2018263975A1
- Authority
- US
- United States
- Prior art keywords
- eltoprazine
- administered
- dose
- administration
- levodopa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 88
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 65
- 230000000694 effects Effects 0.000 title claims abstract description 60
- 238000011282 treatment Methods 0.000 title claims abstract description 60
- 208000019430 Motor disease Diseases 0.000 title claims abstract description 39
- 208000016285 Movement disease Diseases 0.000 title claims description 36
- WVLHGCRWEHCIOT-UHFFFAOYSA-N eltoprazine Chemical compound C1CNCCN1C1=CC=CC2=C1OCCO2 WVLHGCRWEHCIOT-UHFFFAOYSA-N 0.000 claims abstract description 164
- 229950006047 eltoprazine Drugs 0.000 claims abstract description 164
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 95
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 93
- 229960004502 levodopa Drugs 0.000 claims abstract description 90
- 208000012661 Dyskinesia Diseases 0.000 claims abstract description 67
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 5
- 230000036470 plasma concentration Effects 0.000 claims description 28
- 238000011068 loading method Methods 0.000 claims description 18
- 239000002552 dosage form Substances 0.000 claims description 17
- 230000003111 delayed effect Effects 0.000 claims description 12
- 238000013265 extended release Methods 0.000 claims description 12
- 239000006186 oral dosage form Substances 0.000 claims description 10
- 238000013270 controlled release Methods 0.000 claims description 9
- 239000007942 layered tablet Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 7
- 238000013268 sustained release Methods 0.000 claims description 7
- 239000012730 sustained-release form Substances 0.000 claims description 7
- 230000000541 pulsatile effect Effects 0.000 claims description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000003374 anti-dyskinetic effect Effects 0.000 abstract description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 108
- 150000001875 compounds Chemical class 0.000 description 91
- 239000003814 drug Substances 0.000 description 74
- 229940079593 drug Drugs 0.000 description 72
- 229960003638 dopamine Drugs 0.000 description 52
- 239000010410 layer Substances 0.000 description 37
- 239000000018 receptor agonist Substances 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 33
- 102000005962 receptors Human genes 0.000 description 33
- 239000004031 partial agonist Substances 0.000 description 26
- 229940044601 receptor agonist Drugs 0.000 description 25
- 239000003826 tablet Substances 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 23
- 239000000556 agonist Substances 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 12
- 239000000902 placebo Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 238000011287 therapeutic dose Methods 0.000 description 10
- 206010034010 Parkinsonism Diseases 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 8
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 8
- 208000019901 Anxiety disease Diseases 0.000 description 7
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 7
- 208000027089 Parkinsonian disease Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000036506 anxiety Effects 0.000 description 6
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229940052760 dopamine agonists Drugs 0.000 description 6
- 239000005022 packaging material Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 206010020651 Hyperkinesia Diseases 0.000 description 5
- 208000000269 Hyperkinesis Diseases 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- -1 gums Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 239000008184 oral solid dosage form Substances 0.000 description 5
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 4
- 102000015554 Dopamine receptor Human genes 0.000 description 4
- 108050004812 Dopamine receptor Proteins 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940001089 sinemet Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- OTVUCEMFRGJEMR-FTXVUGNJSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(e)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethylprop-2-enamide;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1.CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 OTVUCEMFRGJEMR-FTXVUGNJSA-N 0.000 description 2
- JFSOSUNPIXJCIX-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine;hydron;chloride Chemical compound Cl.C1CNCCN1C1=CC=CC2=C1OCCO2 JFSOSUNPIXJCIX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 241000220479 Acacia Species 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 2
- 241000282461 Canis lupus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- MTYYDFXUUJQQRS-UHFFFAOYSA-N batoprazine Chemical compound C=12OC(=O)C=CC2=CC=CC=1N1CCNCC1 MTYYDFXUUJQQRS-UHFFFAOYSA-N 0.000 description 2
- 229950002408 batoprazine Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229960004596 cabergoline Drugs 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229960004205 carbidopa Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100001079 no serious adverse effect Toxicity 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- QFLMOYQNYBDXMT-ZCMDIHMWSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;2-amino-3-hydroxy-n'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O QFLMOYQNYBDXMT-ZCMDIHMWSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical compound O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010050012 Bradyphrenia Diseases 0.000 description 1
- 102100040999 Catechol O-methyltransferase Human genes 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- GQWNECFJGBQMBO-UHFFFAOYSA-N Molindone hydrochloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- UPMRZALMHVUCIN-UHFFFAOYSA-N Nitecapone Chemical compound CC(=O)C(C(C)=O)=CC1=CC(O)=C(O)C([N+]([O-])=O)=C1 UPMRZALMHVUCIN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 208000008039 Secondary Parkinson Disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010068100 Vascular parkinsonism Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000024453 abnormal involuntary movement Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- AJXBTRZGLDTSST-UHFFFAOYSA-N amino 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)ON AJXBTRZGLDTSST-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940089964 lodosyn Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 235000011160 magnesium carbonates Nutrition 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000010034 metabolic health Effects 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229950008980 nitecapone Drugs 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940026768 parcopa Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940075065 polyvinyl acetate Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229940103422 stalevo Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Definitions
- This invention relates generally to the administration of drugs having agonist activity at 5-HT 1a and/or 5-HT 1b receptors to patients in need thereof in order to prevent, attenuate and/or treat motor disorders, movement disorders and side effects thereof associated with drugs that increase the activity of the dopamine receptor, including dopamine agonists and partial agonists, whether acting directly or indirectly, as well as dopamine precursors, such as levodopa (L-DOPA).
- the invention relates to methods of preventing and treating L-DOPA-induced dyskinesia (LID), and to preventing and treating Parkinson's disease, by administering eltoprazine, particularly in certain doses and dosing or administration regimens, either alone or in combination with other compounds.
- LID L-DOPA-induced dyskinesia
- Parkinson's disease is a chronic, progressive, hypokinetic neurodegenerative disorder characterized by impaired voluntary movement (See, Dale and Federman (eds.), WebMD Scientific American Medicine , NY: WebMD Corporation, Chapter 11, Section 15, pp. 1-21,2001; Lang and Lozano, N Engl J Med, 339: 1044, 1998; and Lang and Lozano, N Engl J Med, 339: 1130, 1998). Parkinson's disease occurs at least as a result of the death of dopamine-producing neurons in the substantia nigra of the midbrain. Dopamine is a neurotransmitter, or chemical messenger, that transports signals to the parts of the brain that control movement initiation and coordination.
- the loss of dopamine in the brain is associated with multiple primary symptoms including, for example, tremor of the hands, arms, legs, jaw, and face; rigidity or stiffness of the limbs and trunk; bradykinesia or slowness of movement; dyskinesia; and postural instability or impaired balance and coordination.
- the disease is also associated with dementia, sleep disturbances and cognitive confusion.
- Parkinson's disease afflicts more than one million persons in the United States alone (Lang and Lozano, supra, 1998), with approximately 50,000 new cases diagnosed each year. It is generally a disease of late middle age, with typical onset occurring at about age 60. About five percent of patients, however, have early-onset disease and are younger than 40 when symptoms begin.
- L-DOPA L-3,4-dihydroxyphenylalanine; levodopa
- L-DOPA can cause debilitating side effects (LeWitt and Nyholm Neurology, 62:S9-S16, 2004), including severe nausea, vomiting, and psychosis.
- Serotonin neurons are reported to play a role in the development of L-DOPA-induced dyskinesia (LID), and specifically, 5-HT 1a and 5-HT 1b receptors are thought to be involved (see, e.g., Carta et al., Brain, 130(7): 1819-33 (2007); and U.S. published application 2007/0249621).
- LID L-DOPA-induced dyskinesia
- 5-HT 1a and 5-HT 1b receptors are thought to be involved (see, e.g., Carta et al., Brain, 130(7): 1819-33 (2007); and U.S. published application 2007/0249621).
- 5-HT 1a and 5-HT 1b receptors were reported to reduce LID (Carta et al., 2007).
- WO2010/063486 to Merz et al. WO 2009/156380 to Bjorklund et al.
- U.S. patent publication 2007/0249621 to Wolf et. al. U.S. patent publication 2010/0179171 to Wolf et. al.
- European Patent Application No. 2193794 to Valastro et al. relate to the use of eltoprazine to treat LID in rats.
- the binding profile of eltoprazine as reported by Sijbesma shows the compound to be a selective 5-HT 1 ligand (selective with respect to all receptors other than 5-HT 1 ) and similar to serotonin in many respects except for a lower affinity for the 5-HT 1d receptor.
- the literature reports that eltoprazine acts as a mixed 5-HT 1a /5-HT 1b receptor agonist with roughly equipotent affinity for each of these receptors (Schipper et al., Drug Metabol Drug Interact, 8(1-2):85-114, (1990)).
- Eltoprazine has no relevant affinity for dopamine receptors.
- the 5-HT 1b receptor is located as an autoreceptor on axon terminals and is responsible for inhibiting neurotransmitter release, whereas it is also located postsynaptically as a heteroreceptor on axons and terminals of non-serotonergic neurons inhibiting their activity (Clark and Neumaier, Psychopharmacol Bul, 35(4): 170-85, (2001)).
- This invention provides methods for preventing, attenuating, and/or treating in patients (preferably humans) with PD, movement disorders, motor disorders, or movement or motor disorder side effects associated with dopamine-related drugs, in addition to preventing, attenuating, and/or treating PD.
- the methods involve treating patients with eltoprazine in certain doses and dose regimens found to be effective in reducing LID in human patients, specifically when eltoprazine is administered to Parkinson's patients at particular doses and dosing intervals.
- LID severity is reduced in LID patients to whom eltoprazine is dosed two or three times daily at 4 hour intervals at doses of 2.5 mg, 5 mg, 7.5 mg and 10 mg.
- eltoprazine is administered to a patient to reduce LID one, two, or three times daily at a dose of 5 mg or 7.5 mg.
- eltoprazine is orally administered.
- eltoprazine is administered in a controlled release, sustained release, extended release, delayed release, or pulsatile release dosage form, such as, without limitation, an oral solid dosage form.
- the oral dosage form is a multi-layered solid dosage form, such as a bi-layered or a tri-layered tablet.
- the invention provides effective and acutely administered doses of eltoprazine which do not affect the efficacy of levodopa treatment, do not affect the therapeutic response to levodopa and are not associated with any serious adverse events in patients undergoing treatment.
- the dopamine-related drugs encompassed by the invention include drugs that increase the activity of the dopamine receptor, including dopamine agonists and partial agonists, whether acting directly or indirectly, as well as dopamine precursors, such as L-DOPA.
- the invention encompasses preventing, attenuating, and/or treating motor disorder side effects, including but not limited to dyskinesia, that are associated with L-DOPA therapy in Parkinson's patients (L-DOPA-induced dyskinesia, LID).
- the methods of the invention comprise administering to a patient in need thereof a therapeutic dose of a compound having agonist activity at both the 5-HT 1a and 5-HT 1b receptors (eltoprazine or batoprazine as non-limiting examples), or two separate compounds having agonist activity, one targeting the 5-HT 1a receptor, and another compound targeting the 5-HT 1b receptor.
- the methods of the invention also encompass preventing, attenuating, and/or treating PD in a patient in need thereof.
- the 5-HT 1a and 5-HT 1b receptor agonist is eltoprazine or eltoprazine hydrochloride.
- the invention encompasses many possible administration strategies including, but not limited to, administration of the 5-HT 1a/1b receptor agonist or partial agonist before or after initiation of L-DOPA or other dopamine-related drug administration, and administration of the 5-HT 1a/1b receptor agonist or partial agonist before or after development of motor disorder side effects.
- Dosage strategies include therapeutic and sub-therapeutic dosages of L-DOPA or other dopamine-related drug.
- this invention encompasses a reduction in the dosage of L-DOPA or other dopamine-related drug after administration of the 5-HT 1a/1b receptor agonist or partial agonist.
- non-limiting examples of daily dosages include from 3 mg to 30 mg; or 2.5 mg, 5.0 mg, 7.5 mg, and 10 mg as embodiments within the scope of the invention.
- Particularly preferred dosages of eltoprazine, in humans, are 5 mg/day and 7.5 mg/day.
- Administration schedules may also be altered to achieve a therapeutically effective concentration of compound to treat the disorder or symptoms described herein.
- the compound may be administered once per day, twice per day, thrice per day, 4 times per day, 5 times per day, 7 times per day or 10 times per day.
- the invention encompasses methods of treating levodopa (L-DOPA) induced dyskinesia (LID) in a subject, preferably a human patient, in need thereof.
- the subject has Parkinson's disease (PD).
- the methods involve administering eltoprazine to a patient in need at a dose and dose regimen to effectively reduce or abrogate LID in the subject.
- the eltoprazine dose is 5 mg or 7.5 mg.
- eltoprazine is administered to the subject once, twice, or three times daily, in particular, two or three times daily.
- eltoprazine is administered to the subject at hourly intervals of 4, 6, 8, and 12 hours, in particular, at 4 hour intervals.
- the methods involve administering eltoprazine to a patient in need at a dose of 5 mg or 7.5 mg to effectively reduce dyskinesia, namely, LID.
- a daytime plasma concentration following eltoprazine administration is in the range of 9 ng/ml to 30 ng/ml; or in the range of 10 ng/ml to 30 ng/ml; or in the range of 9 ng/ml to 17 ng/ml.
- at a dose of 5 mg the plasma concentration of drug (eltoprazine) is approximately 10 ng/ml
- the plasma concentration of drug (eltoprazine) is approximately 17 ng/ml.
- the invention encompasses a variety of daily dosing combinations to achieve a desired and effective target daytime plasma concentration range. Oral dosing and administration is encompassed by the methods.
- the methods of the invention embrace a number of dosing combinations and regimens involving eltoprazine to reduce LID and/or to optimize the daytime plasma concentration in the individual (human patient) undergoing treatment.
- an individual in need is dosed twice daily at four or six hourly intervals with an eltoprazine dose of 2.5 mg, 5 mg, or 7.5 mg.
- the dose is 5 mg.
- the dose is 7.5 mg.
- dosing at four or six hour intervals may optimize the daytime plasma concentration in the individual from 10 AM to 8 PM, for example.
- Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- an individual (human patient) in need is dosed twice daily at four hour intervals with an eltoprazine dose of 2.5 mg, 5 mg, 7.5 mg, or 10 mg.
- the dose is 5 mg.
- the dose is 7.5 mg.
- eltoprazine doses of 5 mg and 7.5 mg may optimize the daytime plasma concentration, for example, from 10 AM to 8 PM. Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- an individual (human patient) in need is dosed three times daily at four hour intervals with an eltoprazine dose of 2.5 mg, 5 mg, or 7.5 mg.
- the dose is 5 mg.
- the dose is 7.5 mg.
- three doses of eltoprazine, such as a 5 mg dose and a 7.5 mg dose may allow maximal plasma concentrations to be achieved, for example, in the late afternoon evening period, extending into the night time. Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- an individual in need may be given a morning loading dose of eltoprazine, followed by another dose at a predetermined interval, such as at midday, with a total daily dose of eltoprazine of 10 mg or 15 mg.
- a predetermined interval such as at midday
- a total daily dose of eltoprazine 10 mg or 15 mg.
- Such a regimen involving a loading dose followed by one or more smaller, ‘top up’ doses may optimize daytime exposure while minimizing the overall dose administered to the individual.
- an individual in need is dosed with eltoprazine three times daily at four hour intervals with a dose of 2.5 mg, 5 mg, or 7.5 mg.
- the dose is 5 mg thrice daily every four hours.
- the dose is 7.5 mg thrice daily every four hours.
- Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- the oral dosage form is not intended to be limiting and thus may include liquid oral dosing forms and solid oral dosage forms, such as pills, capsules, or tablets.
- the dosage form is a controlled release, sustained release, extended release, delayed release, or pulsatile release dosage form.
- the controlled release, sustained release, extended release, delayed release, or pulsatile release dosage form is an oral solid dosage form.
- Multilayered tablets, such as bi-layered and tri-layered tablets as controlled, sustained, delayed, extended, or pulsatile release solid dosage forms are encompassed by the invention.
- Kits comprising one or more of the following are also encompassed by the invention described herein: a compound having agonist activity at both the 5-HT 1a and 5-HT 1b receptors, or two separate compounds having agonist activity, one targeting the 5-HT 1a receptor, and another compound targeting the 5-HT 1b receptor, additional compounds, L-DOPA or other or other dopamine-related drug, and instructions for administration.
- kits include a kit comprising eltoprazine, and a kit comprising eltoprazine, L-DOPA, a DDCI inhibitor and/or COMT inhibitor, and optionally any other compound described herein, plus instructions for administration.
- FIG. 1 shows the efficacy of eltoprazine in treating levodopa-induced dyskinesia patients red using Clinical Dyskinesia Rating Scales (CDRS).
- CDRS Clinical Dyskinesia Rating Scales
- FIG. 2 shows that there is no significant change in the Unified Parkinson's Disease Rating Scales-III (UPDRS-III) of parkinsonian symptoms after eltoprazine administration, indicating that eltoprazine does not adversely interfere with the levodopa efficacy in Parkinson's patients.
- UDRS-III Unified Parkinson's Disease Rating Scales-III
- FIG. 3 shows the results of twice daily dosing with 7.5 mg of eltoprazine at 4, 6, 8 and 12 hourly intervals. As observed, dosing at 4 or 6 hourly intervals optimizes daytime plasma concentration from 10 AM to 8 PM.
- FIG. 4 shows the results of twice daily dosing with 2.5, 5, 7.5 and 10 mg of eltoprazine at 4 hour intervals. As observed, doses of 5 mg and 7.5 mg b.d. (twice per day), given at 4 hour intervals, optimizes daytime plasma concentration from 10 AM to 8 PM.
- FIG. 5 shows the results of three times daily dosing with 2.5 mg, 5 mg, and 7.5 mg of eltoprazine at 4 hour intervals. As observed, three doses, given at 4 hour intervals, achieve maximal plasma concentrations in the late afternoon/evening period into the night time.
- FIG. 6 shows the results of a morning loading dose of eltoprazine, followed by midday ‘top up’ for a total daily dose of 10 mg, or 15 mg.
- a loading dose followed by smaller top up doses may optimize an individual's daytime exposure to drug while minimizing the dose.
- This invention encompasses methods of preventing, attenuating, and/or treating motor disorder side effects in a patient with PD, including but not limited to, dyskinesia or other motor disorder, movement disorder, or motor or movement disorder side effects, that are associated with dopamine-related drugs, in addition to preventing, attenuating, and/or treating PD.
- the methods involve therapeutic doses of a compound having agonist activity at both the 5-HT 1a and 5-HT 1b receptors, such as eltoprazine or a pharmaceutically acceptable salt thereof, and dosing regimens and combinations which optimally provide effective and lasting plasma concentrations of drug in a patient undergoing treatment.
- the method comprises administering to a patient in need thereof a therapeutic dose of a compound having agonist activity at both the 5-HT 1a and 5-HT 1b receptors, or two separate compounds having agonist activity, one targeting the 5-HT 1a receptor, and another compound targeting the 5-HT 1b receptor.
- the invention encompasses administering to the patient in need thereof a compound that targets the same, a similar, or a different drug pathway, one that is useful in treating L-DOPA-induced dyskinesia (LID) or other movement disorders or motor disorder side effects associated with dopamine-related drugs, one that is useful in treating PD, or one that is useful for treating both LID or other movement or motor disorders, or movement or motor disorder side effects associated with dopamine-related drugs and PD.
- LID L-DOPA-induced dyskinesia
- This additional compound may also be useful such that the effective dose of L-DOPA or other dopamine-related drug that is necessary to treat PD is reduced.
- the invention contemplates administering to the patient in need thereof L-DOPA, in addition to a compound that targets the same, a similar, or a different drug pathway, one that is useful in treating L-DOPA-induced dyskinesia (LID), one that is useful in treating PD, or one that is useful for treating both LID or other movement disorders or motor disorder side effects associated with dopamine-related drugs and PD.
- LID L-DOPA-induced dyskinesia
- the dopamine-related drugs encompassed by the invention include drugs that increase the activity of the dopamine receptor, including dopamine agonists and partial agonists, whether acting directly or indirectly, as well as dopamine precursors, such as L-DOPA.
- the dopamine-related drug treatment is L-DOPA therapy.
- the dopamine-related drug may be a dopamine receptor agonist, including, but not limited to bromocriptine, pergolide, cabergoline, apomorphine, and lisuride, or a non-ergoline dopamine agonist, including, but not limited to ropinirole or pramipexole.
- the methods of the invention encompass preventing, attenuating, and/or treating any of the movement disorders, motor disorders, movement disorder side effects, or motor disorder side effects described herein, associated with dopamine-related drug treatments, or a combination of dopamine-related drug treatments, such as a combination of dopamine precursors, a combination of dopamine agonists or partial agonists, and a combination of one or more dopamine precursors and one or more dopamine agonists or partial agonists.
- Dopamine precursors such as L-DOPA are often administered with a DOPA decarboxylase inhibitor (DDCI) (also known as aromatic L-amino acid decarboxylase inhibitors (AAADI)).
- DOPA decarboxylase inhibitor also known as aromatic L-amino acid decarboxylase inhibitors (AAADI)
- Non-limiting examples of such compounds contemplated by the invention include benserazide (Madopar, Prolopa, Modopar, Madopark, Neodopasol, and EC-Doparyl); carbidopa (Lodosyn, Sinemet, Parcopa, and Atamet); and Methyldopa (Aldomet, Aldoril, Dopamet, and Dopegyt).
- L-DOPA or other dopamine precursors are also often administered with compounds that inhibit the action of catechol-O-methyl transferase (COMT inhibitors).
- COMT inhibitors for use in the methods herein include entacapone, tolcapone, and nitecapone.
- the methods of the invention encompass preventing, attenuating, and/or treating any of the movement or motor disorder side effects described herein associated with L-DOPA treatment, or treatment with another dopamine-related drug, L-DOPA treatment or other dopamine-related drug treatment in combination with DDCI (AAADI) treatment, L-DOPA treatment or other dopamine-related drug treatment in combination with COMT inhibitors, and L-DOPA treatment or other dopamine-related drug treatment in combination with DDCI (AAADAI) treatment and COMT inhibitors.
- the methods of the invention encompass preventing, attenuating, and/or treating any of the motor disorder side effects described herein, associated with administering the combination of carbidopa, levodopa, and entacapone.
- the combination of carbidopa, levodopa, and entacapone is administered as Stalevo.
- the methods of the invention encompass preventing, attenuating, and/or treating PD itself, including the movement disorders associated with PD.
- the compound having agonist activity at both the 5-HT 1a and 5-HT 1b receptors is eltoprazine or a pharmaceutically acceptable salt thereof.
- the compound is eltoprazine hydrochloride.
- the invention provides a method of prevention, attenuation, and/or treatment of movement or motor disorder side effects, including but not limited to dyskinesia, that are associated with L-DOPA therapy, such as LID, or other dopamine-related drugs in PD patients comprising administering to a patient in need thereof a therapeutic dose of a compound or a combination of two or more different compounds that acts/act as an agonist or partial agonist at the 5-HT 1a receptor in a dosing regimen involving administering the compound or combination of compounds at certain dosing times and intervals.
- L-DOPA therapy such as LID
- dopamine-related drugs in PD patients comprising administering to a patient in need thereof a therapeutic dose of a compound or a combination of two or more different compounds that acts/act as an agonist or partial agonist at the 5-HT 1a receptor in a dosing regimen involving administering the compound or combination of compounds at certain dosing times and intervals.
- this invention provides a method of prevention, attenuation, and/or treatment of movement or motor disorder side effects, including but not limited to dyskinesia, that are associated with L-DOPA therapy or other dopamine-related drugs in PD patients comprising administering to a patient in need thereof a therapeutic dose of a compound or a combination of two or more different compounds that acts/act as an agonist or partial agonist at the 5-HT 1b receptor.
- this invention provides a method of prevention, attenuation, and/or treatment of movement or motor disorder side effects, including but not limited to dyskinesia, that are associated with L-DOPA therapy or other dopamine-related drugs in Parkinson's patients comprising administering to a patient in need thereof a therapeutic dose of a compound or a combination of two or more different compounds that acts/act as an agonist or partial agonist at both the 5-HT 1a and 5-HT 1b receptors.
- this compound may act as an agonist or partial agonist at both the 5-HT 1a and 5-HT 1b receptors.
- certain compounds may act at solely on one receptor (5-HT 1a or 5-HT 1b ) and certain compounds may act at both receptors.
- each compound acts solely on a particular receptor (5-HT 1a or 5-HT 1b ) with the combination of compounds used resulting in the activity of both receptors.
- at least one compound acts on both receptors.
- all compounds act on both receptors.
- this invention provides a method of prevention, attenuation, and/or treatment of movement or motor disorder side effects, including but not limited to dyskinesia or LID, that are associated with L-DOPA therapy or other dopamine-related drugs in Parkinson's patients comprising administering to a patient in need thereof a therapeutic dose of eltoprazine.
- the invention provides a method of preventing, attenuating, and/or treating Parkinson's disease, comprising administering to a patient in need thereof a dopamine-related drug and most preferably, L-DOPA, in combination with a therapeutic dose of eltoprazine or a pharmaceutically acceptable acid addition salt thereof.
- the invention provides methods for treating one or more symptoms of Parkinson's disease.
- symptoms include but are not limited to dyskinesia, hyperkinesia, speech changes, loss of facial expression, cognitive dysfunction, mood swings, emotional ability, euphoria, bipolar syndrome, anxiety, aphasia, dysphasia, or disturbances, dementia or confusion, depression, fear, anxiety, memory difficulties, slowed thinking, sexual dysfunction, fatigue, aching, and loss of energy.
- NINCDS-ADRDA criteria McKhann et al., 1984
- ICD-IO criteria World Health Organization, 1992
- DSM-IV criteria American Psychiatric Association, 1994.
- Other manuals useful in diagnosing the conditions described herein include for example, but are not limited to Oppenheimer's Diagnostic Neuropathology: A Practice Manual (Esiri and Perl, 2006, Hodder Amold, London.); Harrison's Principles of Internal Medicine (Ed. Kasper et al, 16th Ed.
- Eltoprazine (1-(2,3 -dihydro-1, 4-benzodioxanyl-5-yl) piperazine) is particularly preferred for use in the methods of the invention, including pharmaceutically acceptable salts thereof, and preferably HC1.
- Another preferred compound that may be useful for this invention is batoprazine, (8-(1-piperazine)-2H-1-benzopyran-2-one).
- This invention also includes the use of prodrugs of the compounds of the formulas provided, specifically derivatives of the compounds of the formulas that are inactive but are converted to an active form in the body following administration.
- Eltoprazine and processes for its synthesis are known in the art and is described in U.S. Pat. No. 4,833,142; U.S. Pat. No. 5,424,313; European Patent No. 189,612; and European Patent No. 138,280, each of which is incorporated herein by reference in its entirety.
- Eltoprazine is commercially available, for example, through Tocris Bioscience (Ellisville, Mo.).
- the invention encompasses many possible administration strategies including, but not limited to, administration of the 5-HT 1a/1b receptor agonist or partial agonist before or after initiation of L-DOPA or other dopamine-related drug administration, and administration of the 5-HT 1a/1b receptor agonist or partial agonist before or after development of motor disorder side effects.
- Dosage strategies include therapeutic and sub-therapeutic dosages of L-DOPA or other dopamine-related drug.
- this invention encompasses a reduction in the dosage of L-DOPA or other dopamine-related drug after administration of the 5-HT 1a/1b receptor agonist or partial agonist.
- non-limiting examples of daily dosages include from 3 mg to 30 mg; or 2.5 mg, 5.0 mg, 7.5 mg, and 10 mg as embodiments within the scope of the invention.
- Particularly preferred dosages of eltoprazine, in humans are 5 mg/day and 7.5 mg/day, at one or more dosing intervals.
- Administration schedules may also be altered to achieve a therapeutically effective concentration of compound to treat the disorder or symptoms described herein.
- the compound may be administered once per day, twice per day, thrice per day, 4 times per day, 5 times per day, 7 times per day or 10 times per day.
- the methods of the invention embrace a number of newly determined, antidyskinetic dosing combinations and regimens involving eltoprazine to reduce LID and/or to optimize the daytime plasma concentration in the individual (human patient) undergoing treatment.
- doses of eltoprazine administered to a patient in need thereof in certain dosing schedules or regimens were surprisingly found to be effective in achieving maximal and desired plasma concentrations in the patient with lasting effects.
- daily doses of eltoprazine of 5 mg to 10 mg, preferably 5 mg and 7.5 mg resulted in a daytime plasma concentration in the range of 10 ng/ml to 30 ng/ml.
- the plasma concentration range is 9 ng/ml or 17 ng/ml.
- the methods involve administering eltoprazine to a patient in need at a dose of 5 mg or 7.5 mg to effectively reduce dyskinesia, namely, LID.
- a daytime plasma concentration following eltoprazine administration is in the range of 10 to 30 ng/ml or in the range of 9 to 17 ng/ml.
- the plasma concentration of drug (eltoprazine) is approximately 10 ng/ml
- the plasma concentration of drug (eltoprazine) is approximately 17 ng/ml.
- the invention encompasses a variety of daily dosing combinations to achieve a desired and effective target daytime plasma concentration range. Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- the methods involve administering eltoprazine to a patient in need twice daily at four or six hour intervals with an eltoprazine dose of 2.5 mg, 5 mg, or 7.5 mg. In a particular embodiment, the dose is 5 mg. In another particular embodiment, the dose is 7.5 mg. In an aspect, dosing at four or six hour intervals may achieve optimal daytime plasma concentration in the individual from 10 AM to 8 PM, for example. See, e.g., FIG. 3 . Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- the methods involve administering eltoprazine to a patient in need twice daily at four hour intervals with an eltoprazine dose of 2.5 mg, 5 mg, 7.5 mg, or 10 mg.
- the dose is 5 mg.
- the dose is 7.5 mg.
- eltoprazine doses of 5 mg and 7.5 mg may optimize the daytime plasma concentration, for example, from 10 AM to 8 PM. See, e.g., FIG. 4 . Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- the methods involve administering eltoprazine to a patient in need three times daily at four hour intervals with an eltoprazine dose of 2.5 mg, 5 mg, or 7.5 mg.
- the dose is 5 mg.
- the dose is 7.5 mg.
- three daily doses of eltoprazine, such as a 5 mg dose and a 7.5 mg dose may allow maximal plasma concentrations to be achieved, for example, in the late afternoon evening period, extending into the night time, thus providing longer term reduction in the patient's symptoms. See, e.g., FIG. 5 .
- Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- the methods involve administering a loading dose of eltoprazine to a patient in need, followed by a subsequent dose at a predetermined time thereafter. More particularly, a dose of eltoprazine is administered early in the day, such as a morning loading dose, followed by another dose at a later interval, such as at midday.
- the subsequent, ‘top up’ dose may be administered one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, etc. hours, and intervals there between, after the initial loading dose.
- the subsequent dose may be administered from one to twelve hours after the loading dose; or from two to ten hours after the loading dose; or from two to six hours after the loading dose, etc.
- a total daily dose of eltoprazine may be 10 mg or 15 mg.
- Such a regimen involving a loading dose followed by one or more smaller, ‘top up’ doses, may optimize daytime exposure while minimizing the overall dose administered to the individual. See, e.g., FIG. 6 .
- an individual in need is dosed with a 7.5 mg loading dose of eltoprazine, followed by a 2.5 mg dose of eltoprazine thereafter.
- an individual in need is dosed with a 7.5 mg loading dose of eltoprazine, followed by a 5 mg dose of eltoprazine thereafter. In an embodiment, an individual in need is dosed with a 10 mg loading dose of eltoprazine, followed by a 5 mg dose of eltoprazine thereafter. In an embodiment, an individual in need is dosed with a 10 mg loading dose of eltoprazine, followed by a 2.5 mg dose of eltoprazine thereafter. Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- the oral dosage form is not intended to be limiting and thus may include liquid oral dosing forms and solid oral dosage forms, such as pills, capsules, or tablets.
- Multilayered tablets such as bi-layered and tri-layered tablets are encompassed by the invention.
- controlled release, sustained release, delayed release and extended release solid oral dosage forms are encompassed by the invention.
- eltoprazine and/or a related compound(s) is administered in combination with one or more additional compound(s).
- the additional compound(s) may have actions that are similar to, synergistic to, or different than eltoprazine and/or its related compound(s).
- additional compounds and drugs that may be administered in combination with eltoprazine may be found, for example and without limitation, in U.S. Pre-Grant Publication No. US 2013/0331399, the contents of which are incorporated by reference herein in their entirety.
- eltoprazine and/or a related compound(s) is administered optionally in combination with one or more additional compound(s) for prevention, attenuation, and/or treatment of dyskinesia or other movement or motor disorder or side effect thereof that is associated with L-DOPA therapy or other dopamine-related drugs in Parkinson's patients.
- eltoprazine and/or a related compound(s) is administered optionally in combination with one or more additional compound(s) for prevention, attenuation, and/or treatment of PD.
- L-DOPA is administered to a PD patient in need thereof, and following this administration, by the methods described herein, eltoprazine and/or a related compound(s) is administered.
- the eltoprazine and/or a related compound(s) is administered optionally in combination with one or more additional compound(s) for prevention, attenuation, and/or treatment of dyskinesia that is associated with L-DOPA therapy.
- L-DOPA is administered to a PD patient in need thereof following the administration of eltoprazine and/or a related compound(s) optionally in combination with one or more additional compound(s), for prevention, attenuation, and/or treatment of dyskinesia that is associated with L-DOPA therapy.
- L-DOPA is administered to a PD patient in need thereof, and following this administration, by the methods described herein, eltoprazine and/or a related compound(s) is administered after the development of motor side effects, optionally in combination with one or more additional compound(s), for prevention, attenuation, and/or treatment of dyskinesia that is associated with L-DOPA therapy.
- L-DOPA is administered to a PD patient in need thereof, and following this administration, by the methods described herein, eltoprazine and/or a related compound(s) is administered prior to the development of motor side effects, optionally in combination with one or more additional compound(s), for prevention, attenuation, and/or treatment of dyskinesia that is associated with L-DOPA therapy.
- the invention is not used for prevention, attenuation, and/or treatment of the associated cognitive impairment in PD. In another embodiment, the invention is not used for prevention, attenuation, and/or treatment of any one or more of the following: Alzheimer's disease, Huntington's disease, Cushing's syndrome, Lewy body disease, multiple sclerosis, stroke, addictive disorders, pervasive development disorder, Fragile X syndrome, anxiety disorders, Prader-Willi Syndrome, schizophrenia, bipolar disorder, depressive disorders, vascular dementia, mild cognitive impairment, dementia, or delirium. In an alternative embodiment, the invention may be used for prevention, attenuation, and/or treatment of one or more of these disorders.
- the methods of the invention encompass preventing, attenuating, and/or treating a movement or motor disorder, or a movement or motor side effect associated with a dopamine-related drug for the treatment of PD, which is not L-DOPA.
- the invention encompasses preventing, attenuating, and/or treating in patients with PD, movement disorders, motor disorders or side effects thereof associated with dopamine-related drugs, in addition to preventing, attenuating, and/or treating PD, by administering to a patient in need thereof a therapeutic dose of a compound having agonist activity at both the 5-HT 1a and 5-HT 1b receptors, or two separate compounds having agonist activity, one targeting the 5-HT 1a receptor, and another compound targeting the 5-HT 1b receptor, in combination with deep brain stimulation as performed in a surgical procedure, or in combination with magnetic brain stimulation, such as transcranial magnetic stimulation.
- the invention encompasses preventing, attenuating, and/or treating in patients with PD, movement disorders, or motor disorder side effects associated with dopamine-related drugs, in addition to preventing, attenuating, and/or treating PD, by administering to a patient in need thereof a therapeutic dose of eltoprazine in combination with deep brain stimulation and/or transcranial magnetic stimulation, and optionally in combination with any other compound described herein.
- a therapeutic dose of eltoprazine in combination with deep brain stimulation and/or transcranial magnetic stimulation, and optionally in combination with any other compound described herein.
- the deep brain stimulation and/or transcranial magnetic stimulation may precede the dopamine-related drug treatment, may follow the dopamine-related drug treatment, may precede the eltoprazine treatment, or may follow the eltoprazine treatment.
- the doses of the compounds used in treating the disorders described herein in accordance with this invention will vary in the usual way with the seriousness of the disorder, the weight, and metabolic health of the individual in need of treatment.
- the methods of the invention provide therapeutically effective doses and treatment schedules for administration to individual patients to arrive at the desired therapeutic or prophylactic effect, including a desired plasma concentration, while minimizing side effects.
- Particularly beneficial doses of eltoprazine for providing a more sustained effect include a 5 mg dose and a 7.5 mg dose.
- the 5 mg and the 7.5 mg doses of eltoprazine are administered to a patient three times daily.
- the 5 mg and the 7.5 mg doses of eltoprazine are administered to a patient three times daily at four hour intervals.
- Administration schedules may also be altered to achieve other therapeutically effective concentrations of compound to treat the disorders or symptoms described herein.
- the methods described herein reflect the discovery of particular efficacious doses of eltoprazine and dosing schedules that achieve plasma concentrations in treated individuals for reducing and/or treating levodopa-induced dyskinesia in Parkinson's patients.
- the particularly efficacious doses and schedules are 5 mg and 7.5 mg of eltoprazine administered two or three times per day at four hour intervals, for example, as shown in FIGS. 4 and 5 herein.
- Example 1 and FIG. 2 also show that administration of eltoprazine to Parkinson's patients already on levodopa treatment who then receive eltoprazine do not show a reduction in the efficacy of levodopa therapy for treating PD. Further, eltoprazine was well-tolerated, and there were no serious adverse events from administration.
- eltoprazine and/or related compounds may be administered once per day, twice per day, thrice per day, 4 times per day, 5 times per day, 7 times per day or 10 times per day. In preferred embodiments, eltoprazine is administered one, two, or three times per day. Often the dosage is divided equally throughout the day, however in some embodiments to treat certain disorders or symptoms, it may be useful to bias the dosage administration schedule so that most of the daily treatment is administered at the beginning half or portion of the day. In some embodiments, about 50%, 60%, 70% or 80% of the dosage is administered in the first half or portion of the day. In other embodiments, it may be more appropriate to administer most of the dosage in the latter half or portion of the day so that about 50%, 60% , 70% or 80% of the dosage is administered in the latter half or portion of the day.
- the 5-HT 1a/1b receptor agonist, partial agonist, or agonists and, optionally, at least one additional compound may be administered before, concurrently, or after administration of L-DOPA or other dopamine-related drug.
- the 5-HT 1a/1b receptor agonist, partial agonist, or agonists and, optionally, at least one additional compound is administered before administration of L-DOPA or other dopamine-related drug.
- the dose of L-DOPA or other dopamine-related drug is reduced.
- the 5-HT 1a/1b receptor agonist, partial agonist, or agonists may be administered before, concurrently, or after administration of at least one additional compound.
- the 5-HT 1a/1b receptor agonist, partial agonist, or agonists and, optionally, at least one additional compound may be administered before, concurrently, or after onset of symptoms.
- the symptoms include a movement or motor disorder, or a movement or motor disorder side effect from the use of L-DOPA or other dopamine-related drugs.
- the 5-HT 1a/1b receptor agonist and, optionally, at least one additional compound is/are administered after the development of a movement or motor disorder side effect.
- the 5-HT 1a/1b receptor agonist, partial agonist, or agonists and, optionally, at least one additional compound is/are administered before the development of a movement or motor disorder side effect.
- Administration of the compounds of this invention may be by any method used for administering therapeutics, such as for example, oral, parenteral, intravenous, intramuscular, subcutaneous, rectal, or topical administration, such as through the use of a transdermal patch.
- eltoprazine is orally administered to a patient in need.
- age of the patient with the conditions described herein may respond to treatment at different degrees depending on factors such as dosage or administration or the presence of other factors or co-morbid conditions. Therefore, one of ordinary skill in the art will appreciate that the methods described herein may be directed to a particular age group.
- the pharmaceutical compositions for use with this invention may also comprise a pharmaceutically acceptable carrier.
- Such carriers may comprise additives, such as preservatives, excipients, fillers, wetting agents, binders, disintegrants, buffers may also be present in the compositions of the invention.
- Suitable additives may be, for example magnesium and calcium carbonates, carboxymethylcellulose, starches, sugars, gums, magnesium or calcium stearate, coloring or flavoring agents, and the like.
- Suitable additives may be, for example magnesium and calcium carbonates, carboxymethylcellulose, starches, sugars, gums, magnesium or calcium stearate, coloring or flavoring agents, and the like.
- compositions for use in the methods may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions.
- a composition of the invention is in the form of a unit dose.
- Unit dose forms for oral administration may be tablets, capsules, and the like, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; and carriers or fillers, for example, lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine.
- Additives may include disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycolate or microcrystalline cellulose; preservatives, and pharmaceutically acceptable wetting agents such as sodium lauryl sulfate.
- multi-dosage forms are also contemplated to be within the scope of the invention.
- Modified or controlled release dosage forms are contemplated for use in the invention, including, but not limited to, controlled release dosage forms, sustained release dosage forms, extended release dosage forms, delayed release dosage forms, and pulsatile release dosage forms.
- the 5-HT 1a/1b receptor agonist such as eltoprazine or a pharmaceutically acceptable salt thereof, is administered in an oral solid dosage form.
- the oral solid dosage form may be a pill, capsule, caplet, or tablet.
- eltoprazine is administered in the form of a multi-layered tablet, such as a bi-layered or a tri-layered tablet.
- the methods encompass the administration of eltoprazine as the active ingredient in a bi- or tri-layered oral solid dosage form as a single daily dose, as described herein.
- Suitable polymers for use in the controlled release formulations of the present invention include, but are not limited to uncrosslinked, linear polymers including cellulosic polymers, preferably hydroxyethyl cellulose, sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose and hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, and ethyl cellulose, and combinations thereof; covalently crosslinked insoluble polymers such as high molecular weight crosslinked homopolymers and copolymers of (meth) acrylic acid including carbopol resins, or mixtures of these uncrosslinked and covalently crosslinked polymers.
- uncrosslinked, linear polymers including cellulosic polymers, preferably hydroxyethyl cellulose, sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose and hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, and ethyl cellulose, and combinations thereof; covalently crosslinked insoluble polymers such as high molecular weight crosslinked homopolymers and
- suitable polymers include acrylic acid, methacrylic acid, methyl acrylate, ammonio methylacrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate, vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, polyvinylacetate phthalate, vinylacetate crotonic acid copolymer, and ethylene-vinyl acetate copolymers, to name a few.
- Various combinations of two or more of the above polymers are also contemplated for use in the dosage forms of the invention.
- Delayed release compositions may be prepared, for example, by employing slow release coatings, micro encapsulation, and/or slowly dissolving polymers.
- the solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art.
- the tablets may be coated according to methods well known in normal pharmaceutical practice, for example, with an enteric coating.
- Multilayered tablets may be produced by processes and procedures known and available in the art. See, e.g., EP 1681051 and EP 2517696 A1, as relates to the following.
- the tablet comprises multiple layers having different time release profiles.
- the tablet may have two, three, four or five layers, in which, for example, the first layer is formulated for immediate release and the second layer is formulated for delayed release.
- the third layer may be formulated to have a release that is later than the second layer.
- the third layer is located in the middle of the tablet.
- the layers having the longest delay are formulated to be nearest the center of the multi-layer tablet, either in horizontal layers, or in the form of a core coated by subsequent layers.
- such a layer is formulated with one or more rate-controlling polymers and pharmaceutically acceptable excipients generally known in the art for immediate release.
- such a layer is formulated with one or more rate-controlling polymers and pharmaceutically acceptable excipients generally known in the art for immediate release.
- the rate-controlling polymer is a polyethylene oxide polymer. The molecular weight of the polyethylene oxide molecule of the polyethylene oxide polymer used may be 7,000,000 g/mole and Brookfield viscosity of its 1% m/v aqueous solution at 25° C. is 7500-10000 cps (Colorcon-Sentry Polyox WSR 303-Leo-NF-Dow).
- the tablet developed is composed of two layers, with one of the layers providing immediate release, and the other layer providing extended release.
- 65-85% of the active ingredient (API) content of the tablet may be present at the extended release providing layer and 15-35% may be present at the immediate release providing layer.
- the two separate layers may be compressed as two layer tablet.
- the layer providing extended release forms the tablet core and the layer providing immediate release is coated on the tablet core.
- the immediate release layer provides extended release between 20% to 40% in the first hour in order to provide the adequate effective blood level and two-phase pellets to achieve C max value.
- Excipients known in the art may be used to formulate the extended release providing layer, including, but not limited to, calcium phosphate dibasic as buffer agent, talc and magnesium stearate as lubricant and colloidal silicon dioxide (Aerosil 200) as glidant.
- Excipients known in the art may be used to formulate the immediate release providing layer, including, but not limited to, microcrystalline cellulose as diluent and binder, croscarmellose sodium as disintegrant, magnesium stearate as lubricant and colloidal silicon as glidant.
- Rate controlling polymers employed in multi-layered tablet forms containing one or more active ingredients may be one or more of hydrophilic polymers, hydrophobic polymers or a combination thereof.
- the one or more rate-controlling polymers may comprise about 5% to about 60% w/w of the tablet.
- Hydrophilic polymers in multi-layer tablet forms may be one or more of cellulose derivatives comprising hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose or combinations thereof; polyvinylpyrrolidone, vinyl acetate/vinyl-pyrrolidone copolymer, microcrystalline cellulose, polysaccharides, polyalkylene glycols, starch and derivatives thereof.
- the hydrophobic polymers in multi-layer tablet forms may be one or more of ethyl cellulose, cellulose acetate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, poly (alkyl) methacrylate, and copolymers of acrylic or methacrylic acid esters, waxes, shellac and hydrogenated vegetable oils.
- the layers may be prepared by one or more of dry granulation, wet granulation or direct compression.
- the layer containing the active ingredient may further include an alkalizing agent.
- the tablet may further include one or both of an outer protective coating layer or a separating layer between first and second layers.
- the tablet may exhibit a T max of one active which occurs at a time 4 hours to about 10 hours and exhibits a T max of another active which occurs at a time 5 hours to about 18 hours after administration of the tablet to a human patient. See, e.g., WO 2006092711 A2.
- Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, and hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil or fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavoring or coloring agents.
- suspending agents for example sorbitol syrup, methyl cellulose, gelatin,
- fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle.
- the compound can be dissolved in water or saline for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
- additives such as a local anesthetic, preservative and buffering agent can be dissolved in the vehicle.
- Suitable buffering agents are, for example, phosphate and citrate salts.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
- the compound can be sterilized by conventional means, for example by exposure to radiation or ethylene oxide, before being suspended in the sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- kits may comprise at least one 5-HT 1a/1b receptor agonist, partial agonist, or agonists, and at least one additional compound.
- a kit may comprise at least one 5-HT 1a/1b receptor agonist, partial agonist, or agonists, L-DOPA or other dopamine-related drug, and optionally at least one additional compound, such as set forth, for example, in U.S. Pre-Grant Publication No. US 2013/0331399, the contents of which are incorporated by reference herein in their entirety.
- the kit may also include instructions for administration of the compounds.
- kits are intended for use by a subject having PD.
- a kit may comprise at least one 5-HT 1a/1b receptor agonist, partial agonist, or agonists, at least one dopamine precursor, at least one DDCI, and instructions for administering the compounds.
- a kit may comprise at least one 5-HT 1a/1b receptor agonist, partial agonist, or agonists, at least one dopamine precursor, at least one DDCI, at least one COMT inhibitor, and instructions for administering the compounds.
- the at least one 5-HT 1a/1b receptor agonist is eltoprazine.
- This example describes a multicenter, randomized, double-blind, placebo-controlled, dose finding study of oral eltoprazine in Parkinson's patients with L-DOPA induced dyskinesias, in a levodopa challenge-dose setting in Parkinson's Disease.
- a total of 22 patients participated in the study, out of which 18 patients fulfilled the protocol in terms of eligibility, interventions, and outcome assessment.
- Each patient had Parkinson's disease, defined according to the UK Brain Bank Criteria (see Hughes et al., J Neurol Neurosurg Psychiatry, 1992. 55(3): p. 181-4; Lees et al., Lancet, 2009. 373: p. 2055-66). Bradykinesia symptoms were combined with one of resting tremor, rigidity or postural imbalance. 2. Each patient had been treated for at least 3 years with L-DOPA prior to this study. 3. Each patient had significant dyskinesias after L-DOPA dosages according to clinical experience. 4. Each patient had significant dyskinesias after the administration of a single challenge dose of L-DOPA using two dyskinesia rating scales.
- the screening test was performed with a challenge dose of 150% of the normal regular dose of L-DOPA. If no dyskinesias was present during the first challenge, the challenge was repeated on an alternate day (and) significant dyskinesias in a patient self-administered diary with 3 levels with 3 grades (“off,” “on without dyskinesias,” “on with hyperkinesias”) after the challenge dose has been given. Patients were included if one of the two challenge tests were positive and diary was positive for dyskinesias.
- Reduced liver function defined as aspartate aminotransferase, ASAT>1.0 ⁇ kat/L or alanine aminotransferase, ALAT>1.0 ⁇ kat/L or glutamyl transpeptidase, GT>1.6 ⁇ kat/L, or total bilirubin>30 ⁇ mol/L, or alkaline phosphatase, ALP>6.0 ⁇ kat/L. 10. History of any other medical condition thought to interfere with the study or study medication (i.e., recent myocardial infarction, uncontrolled diabetes, uncontrolled hypertension (systolic blood pressure>180 mmHg), ongoing severe infection). 11.
- This study also assessed the safety and tolerability of eltoprazine in adults with Parkinson's Disease using the following measures: a) population mean values for the change in dyskinesia ratings between the placebo and screening baseline values and any of the eltoprazine dosages used, calculated as the peak-effect on CDRS of any study medication; b) population mean values for the change in dyskinesia ratings between the placebo and screening baseline values and any of the eltoprazine dosages used, calculated as the AuC on Rush DRS of any study medication; c) any changes in the UPDRS-III total score; d) any change in the diary data set, between the baseline and placebo and any of the three study medication tests; e) any deterioration of the HADS scores after study medication compared with placebo; f) any development of depression over the course of the study period, determined by the Montgomery Asberg Depression Rating Scale (MADRS) and clinical judgment; g) comparison between the effects on Rush Dyskinesia Rating Scale (DRS) and Clinical Dyskinesi
- the study consisted of 7 visits, described below: a screening visit, five treatment visits, and one end-of-study visit.
- L-DOPA was administered as Sinemet (L-DOPA combined with carbidopa in a fixed ratio of 4:1, unless a patient has a known allergy or intolerance to this drug). If a patient is intolerant to Sinemet, an equivalent dose of Madopar Quick could be used. There was an observation period of 3 hours (6 ⁇ 30 min, or 180 minutes) after dosing.
- each patient received a challenge dosage (150%—up to a maximum of 250 mg) of levodopa. Additionally, during each of the five treatment visits, patients were also treated with single dose treatments of oral capsules of three active study medication dosages (2.5 mg, 5 mg, or 7.5 mg of eltoprazine) or two placebo doses. The patients were periodically recorded for 180 minutes after treatment, and the videos were evaluated in a blinded manner.
- Visit 2 occurred within 30 days of visit 1, and visits 3-6 followed one week apart from each other.
- Unified Parkinson's Disease Rating Scale-III and “UPDRS-III” refer to a standardized tool used to measure Parkinson's Disease severity, as described by Fahn et al., in Recent Developments in Parkinson's Disease, Fahn et al. (eds.) Plurham Park, N.J.: Macmillian Healthcare Information, 2:153-163,1987.
- CDRS Cosmetic Dyskinesia Rating Scale
- AIMS abnormal involuntary movement scale
- This scale can simultaneously rate dystonia and dyskinesias, as described by Goetz et al., in Movement Disorders, Vol. 9, No. 4, 1994, 390-394.
- Rush Dyskinesia Rating Scale and “Rush DRS” refer to an observer-based rating scale based on fixed movements.
- the numerical parts of the Rush DRS are recorded separately from the descriptive parts, as described by Goetz et al., in Movement Disorders, Vol. 9, No. 4, 1994, 390-394.
- HADS Hospital Anxiety & Depression Scale
- the term “Montgomery- ⁇ sberg Depression Rating Scale” and “MADRS” refer to an observer based ten-item diagnostic questionnaire used by psychiatrists to measure the severity of depressive episodes in patients with mood disorders, as described by Montgomery et al., in British Journal of Psychiatry 134 (4): 382-89.
- dyskinesia Patients presenting clinically with motor disorder side effects associated with L-DOPA therapy, including dyskinesia, were evaluated using the United Parkinson's Disease Rating Scale III ( Recent Developments in Parkinson's Disease , vol. 2, Fahn et al. editors, Macmillan Publishing Co. Inc, 1987), an art-recognized dyskinesia severity scale (Marconi et al., Mov Disord, 9:2-12, (1994)). Briefly, the dyskinesia severity scale rates abnormal movements from 0 (none) to 4 (severe with markedly impaired function) in six different parts of the body (face, neck, and trunk, and four limbs).
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering eltoprazine or a pharmaceutically acceptable acid addition salt thereof in doses and dosing schedules which result in beneficial antidyskinetic effects for the subject. In particular, the invention provides methods for reducing dyskinesia associated with Parkinson's disease treatments, and effective doses and dosing regimens of eltoprazine or a pharmaceutically acceptable acid addition salt thereof.
Description
- This invention relates generally to the administration of drugs having agonist activity at 5-HT1a and/or 5-HT1b receptors to patients in need thereof in order to prevent, attenuate and/or treat motor disorders, movement disorders and side effects thereof associated with drugs that increase the activity of the dopamine receptor, including dopamine agonists and partial agonists, whether acting directly or indirectly, as well as dopamine precursors, such as levodopa (L-DOPA). In particular, the invention relates to methods of preventing and treating L-DOPA-induced dyskinesia (LID), and to preventing and treating Parkinson's disease, by administering eltoprazine, particularly in certain doses and dosing or administration regimens, either alone or in combination with other compounds.
- Parkinson's disease is a chronic, progressive, hypokinetic neurodegenerative disorder characterized by impaired voluntary movement (See, Dale and Federman (eds.), WebMD Scientific American Medicine, NY: WebMD Corporation, Chapter 11,
Section 15, pp. 1-21,2001; Lang and Lozano, N Engl J Med, 339: 1044, 1998; and Lang and Lozano, N Engl J Med, 339: 1130, 1998). Parkinson's disease occurs at least as a result of the death of dopamine-producing neurons in the substantia nigra of the midbrain. Dopamine is a neurotransmitter, or chemical messenger, that transports signals to the parts of the brain that control movement initiation and coordination. The loss of dopamine in the brain is associated with multiple primary symptoms including, for example, tremor of the hands, arms, legs, jaw, and face; rigidity or stiffness of the limbs and trunk; bradykinesia or slowness of movement; dyskinesia; and postural instability or impaired balance and coordination. The disease is also associated with dementia, sleep disturbances and cognitive confusion. - Parkinson's disease afflicts more than one million persons in the United States alone (Lang and Lozano, supra, 1998), with approximately 50,000 new cases diagnosed each year. It is generally a disease of late middle age, with typical onset occurring at about age 60. About five percent of patients, however, have early-onset disease and are younger than 40 when symptoms begin.
- Most reported treatment strategies for PD focus on symptom control through one or more of medication, surgery, and physical therapy. Administration of the dopamine precursor, L-DOPA (L-3,4-dihydroxyphenylalanine; levodopa) is reported as the most effective and most commonly used treatment for PD, as it reverses the motor deficits associated with PD more so than dopamine agonists (Goodman & Gillman's The Pharmacological Basis of Therapeutics, 11th edition, L. Brunton editor, The McGraw Hill Company, 2006). Unfortunately, L-DOPA can cause debilitating side effects (LeWitt and Nyholm Neurology, 62:S9-S16, 2004), including severe nausea, vomiting, and psychosis. Moreover, with prolonged use, patients frequently experience other side effects such as dyskinesia, or abnormal, excessive movements in many patients, which can interfere with the management of PD (see, e.g., Baldessarini R J., Am. J. Psychiatry, 137: 1163-72 (1980); Samii et al., Lancet, 363(9423): 1783-93 (2004)).
- Serotonin neurons are reported to play a role in the development of L-DOPA-induced dyskinesia (LID), and specifically, 5-HT1a and 5-HT1b receptors are thought to be involved (see, e.g., Carta et al., Brain, 130(7): 1819-33 (2007); and U.S. published application 2007/0249621). In rats, activation of 5-HT1a and 5-HT1b receptors, either separately, or in combination, was reported to reduce LID (Carta et al., 2007). When administered together at certain low doses, 5-HT1a and 5-HT1b receptor agonists were stated to block LID in rats (Carta et al., 2007). WO2010/063486 to Merz et al., WO 2009/156380 to Bjorklund et al.; U.S. patent publication 2007/0249621 to Wolf et. al.; U.S. patent publication 2010/0179171 to Wolf et. al.; and European Patent Application No. 2193794 to Valastro et al. relate to the use of eltoprazine to treat LID in rats.
- The binding profile of eltoprazine as reported by Sijbesma (Sijbesma, H. et al., European Journal of Pharmacology, 187(2): 209-223, (1990)) shows the compound to be a selective 5-HT1 ligand (selective with respect to all receptors other than 5-HT1) and similar to serotonin in many respects except for a lower affinity for the 5-HT1d receptor. The literature reports that eltoprazine acts as a mixed 5-HT1a/5-HT1b receptor agonist with roughly equipotent affinity for each of these receptors (Schipper et al., Drug Metabol Drug Interact, 8(1-2):85-114, (1990)). Eltoprazine has no relevant affinity for dopamine receptors. Among the 5-HT receptors, the 5-HT1b receptor is located as an autoreceptor on axon terminals and is responsible for inhibiting neurotransmitter release, whereas it is also located postsynaptically as a heteroreceptor on axons and terminals of non-serotonergic neurons inhibiting their activity (Clark and Neumaier, Psychopharmacol Bul, 35(4): 170-85, (2001)).
- There exists a need to develop noninvasive treatment methods which can effectively prevent, attenuate, control, and treat the motor disorders, movement disorders, and side effects of the movement and motor disorders associated with drug treatments for PD. There is a need to prevent, attenuate, and treat L-DOPA-induced dyskinesia (LID), as well as to prevent, attenuate, and treat Parkinson's disease (PD). In particular, there is a need to develop strategies that target serotonin receptors, including 5-HT1a and 5-HT1b receptors, either in combination or separately, for the prevention, attenuation and treatment of movement disorders, such as L-DOPA-induced dyskinesia, associated with Parkinson's disease treatments. There is also a need to develop treatment strategies for controlling the symptoms of Parkinson's disease and other movement disorders and effective pharmaceutical compounds and dosages for treating these symptoms. In addition, there is a need for specific therapy regimens that maximize the efficacy, and reduce the side effects of existing medicines, for Parkinson's disease.
- This invention provides methods for preventing, attenuating, and/or treating in patients (preferably humans) with PD, movement disorders, motor disorders, or movement or motor disorder side effects associated with dopamine-related drugs, in addition to preventing, attenuating, and/or treating PD. The methods involve treating patients with eltoprazine in certain doses and dose regimens found to be effective in reducing LID in human patients, specifically when eltoprazine is administered to Parkinson's patients at particular doses and dosing intervals. In an particular embodiment, LID severity is reduced in LID patients to whom eltoprazine is dosed two or three times daily at 4 hour intervals at doses of 2.5 mg, 5 mg, 7.5 mg and 10 mg. In a particular embodiment, eltoprazine is administered to a patient to reduce LID one, two, or three times daily at a dose of 5 mg or 7.5 mg. In an embodiment, eltoprazine is orally administered. In an embodiment, eltoprazine is administered in a controlled release, sustained release, extended release, delayed release, or pulsatile release dosage form, such as, without limitation, an oral solid dosage form. In an embodiment, the oral dosage form is a multi-layered solid dosage form, such as a bi-layered or a tri-layered tablet. The invention provides effective and acutely administered doses of eltoprazine which do not affect the efficacy of levodopa treatment, do not affect the therapeutic response to levodopa and are not associated with any serious adverse events in patients undergoing treatment.
- The dopamine-related drugs encompassed by the invention include drugs that increase the activity of the dopamine receptor, including dopamine agonists and partial agonists, whether acting directly or indirectly, as well as dopamine precursors, such as L-DOPA. In preferred embodiments, the invention encompasses preventing, attenuating, and/or treating motor disorder side effects, including but not limited to dyskinesia, that are associated with L-DOPA therapy in Parkinson's patients (L-DOPA-induced dyskinesia, LID). The methods of the invention comprise administering to a patient in need thereof a therapeutic dose of a compound having agonist activity at both the 5-HT1a and 5-HT1b receptors (eltoprazine or batoprazine as non-limiting examples), or two separate compounds having agonist activity, one targeting the 5-HT1a receptor, and another compound targeting the 5-HT1b receptor. The methods of the invention also encompass preventing, attenuating, and/or treating PD in a patient in need thereof. In particular embodiments, the 5-HT1a and 5-HT1b receptor agonist is eltoprazine or eltoprazine hydrochloride.
- The invention encompasses many possible administration strategies including, but not limited to, administration of the 5-HT1a/1b receptor agonist or partial agonist before or after initiation of L-DOPA or other dopamine-related drug administration, and administration of the 5-HT1a/1b receptor agonist or partial agonist before or after development of motor disorder side effects. Dosage strategies include therapeutic and sub-therapeutic dosages of L-DOPA or other dopamine-related drug. In certain embodiments, this invention encompasses a reduction in the dosage of L-DOPA or other dopamine-related drug after administration of the 5-HT1a/1b receptor agonist or partial agonist. In instances where eltoprazine is used as the 5-HT1a/1b receptor agonist, non-limiting examples of daily dosages include from 3 mg to 30 mg; or 2.5 mg, 5.0 mg, 7.5 mg, and 10 mg as embodiments within the scope of the invention. Particularly preferred dosages of eltoprazine, in humans, are 5 mg/day and 7.5 mg/day. Administration schedules may also be altered to achieve a therapeutically effective concentration of compound to treat the disorder or symptoms described herein. In some embodiments, for example, the compound may be administered once per day, twice per day, thrice per day, 4 times per day, 5 times per day, 7 times per day or 10 times per day.
- The invention encompasses methods of treating levodopa (L-DOPA) induced dyskinesia (LID) in a subject, preferably a human patient, in need thereof. In an embodiment, the subject has Parkinson's disease (PD). In embodiments, the methods involve administering eltoprazine to a patient in need at a dose and dose regimen to effectively reduce or abrogate LID in the subject. In a particular embodiment, the eltoprazine dose is 5 mg or 7.5 mg. In other particular embodiments, eltoprazine is administered to the subject once, twice, or three times daily, in particular, two or three times daily. In an embodiment, eltoprazine is administered to the subject at hourly intervals of 4, 6, 8, and 12 hours, in particular, at 4 hour intervals.
- In particular embodiments, the methods involve administering eltoprazine to a patient in need at a dose of 5 mg or 7.5 mg to effectively reduce dyskinesia, namely, LID. In embodiments, a daytime plasma concentration following eltoprazine administration is in the range of 9 ng/ml to 30 ng/ml; or in the range of 10 ng/ml to 30 ng/ml; or in the range of 9 ng/ml to 17 ng/ml. In particular embodiments, at a dose of 5 mg, the plasma concentration of drug (eltoprazine) is approximately 10 ng/ml, while at a dose of 7.5 mg, the plasma concentration of drug (eltoprazine) is approximately 17 ng/ml. The invention encompasses a variety of daily dosing combinations to achieve a desired and effective target daytime plasma concentration range. Oral dosing and administration is encompassed by the methods.
- The methods of the invention embrace a number of dosing combinations and regimens involving eltoprazine to reduce LID and/or to optimize the daytime plasma concentration in the individual (human patient) undergoing treatment. In an embodiment, an individual in need is dosed twice daily at four or six hourly intervals with an eltoprazine dose of 2.5 mg, 5 mg, or 7.5 mg. In a particular embodiment, the dose is 5 mg. In another particular embodiment, the dose is 7.5 mg. In an aspect, dosing at four or six hour intervals may optimize the daytime plasma concentration in the individual from 10 AM to 8 PM, for example. Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- In an embodiment related to dosing and dosing regimens of eltoprazine, an individual (human patient) in need is dosed twice daily at four hour intervals with an eltoprazine dose of 2.5 mg, 5 mg, 7.5 mg, or 10 mg. In a particular embodiment, the dose is 5 mg. In another particular embodiment, the dose is 7.5 mg. In an aspect, eltoprazine doses of 5 mg and 7.5 mg may optimize the daytime plasma concentration, for example, from 10 AM to 8 PM. Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- In another embodiment related to dosing and dosing regimens of eltoprazine, an individual (human patient) in need is dosed three times daily at four hour intervals with an eltoprazine dose of 2.5 mg, 5 mg, or 7.5 mg. In a particular embodiment, the dose is 5 mg. In another particular embodiment, the dose is 7.5 mg. In an aspect, three doses of eltoprazine, such as a 5 mg dose and a 7.5 mg dose, may allow maximal plasma concentrations to be achieved, for example, in the late afternoon evening period, extending into the night time. Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- In another embodiment, an individual in need (human patient) may be given a morning loading dose of eltoprazine, followed by another dose at a predetermined interval, such as at midday, with a total daily dose of eltoprazine of 10 mg or 15 mg. Such a regimen involving a loading dose followed by one or more smaller, ‘top up’ doses, may optimize daytime exposure while minimizing the overall dose administered to the individual. In an embodiment, an individual in need is dosed with eltoprazine three times daily at four hour intervals with a dose of 2.5 mg, 5 mg, or 7.5 mg. In a particular embodiment, the dose is 5 mg thrice daily every four hours. In another particular embodiment, the dose is 7.5 mg thrice daily every four hours. Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- In embodiments related to oral dosing of eltoprazine and the dosing regimens herein described, the oral dosage form is not intended to be limiting and thus may include liquid oral dosing forms and solid oral dosage forms, such as pills, capsules, or tablets. In an embodiment, the dosage form is a controlled release, sustained release, extended release, delayed release, or pulsatile release dosage form. In an embodiment, the controlled release, sustained release, extended release, delayed release, or pulsatile release dosage form is an oral solid dosage form. Multilayered tablets, such as bi-layered and tri-layered tablets as controlled, sustained, delayed, extended, or pulsatile release solid dosage forms are encompassed by the invention.
- Kits comprising one or more of the following are also encompassed by the invention described herein: a compound having agonist activity at both the 5-HT1a and 5-HT1b receptors, or two separate compounds having agonist activity, one targeting the 5-HT1a receptor, and another compound targeting the 5-HT1b receptor, additional compounds, L-DOPA or other or other dopamine-related drug, and instructions for administration. Non-limiting examples of such kits include a kit comprising eltoprazine, and a kit comprising eltoprazine, L-DOPA, a DDCI inhibitor and/or COMT inhibitor, and optionally any other compound described herein, plus instructions for administration.
-
FIG. 1 shows the efficacy of eltoprazine in treating levodopa-induced dyskinesia patients red using Clinical Dyskinesia Rating Scales (CDRS). -
FIG. 2 shows that there is no significant change in the Unified Parkinson's Disease Rating Scales-III (UPDRS-III) of parkinsonian symptoms after eltoprazine administration, indicating that eltoprazine does not adversely interfere with the levodopa efficacy in Parkinson's patients. -
FIG. 3 shows the results of twice daily dosing with 7.5 mg of eltoprazine at 4, 6, 8 and 12 hourly intervals. As observed, dosing at 4 or 6 hourly intervals optimizes daytime plasma concentration from 10 AM to 8 PM. -
FIG. 4 shows the results of twice daily dosing with 2.5, 5, 7.5 and 10 mg of eltoprazine at 4 hour intervals. As observed, doses of 5 mg and 7.5 mg b.d. (twice per day), given at 4 hour intervals, optimizes daytime plasma concentration from 10 AM to 8 PM. -
FIG. 5 shows the results of three times daily dosing with 2.5 mg, 5 mg, and 7.5 mg of eltoprazine at 4 hour intervals. As observed, three doses, given at 4 hour intervals, achieve maximal plasma concentrations in the late afternoon/evening period into the night time. -
FIG. 6 shows the results of a morning loading dose of eltoprazine, followed by midday ‘top up’ for a total daily dose of 10 mg, or 15 mg. A loading dose followed by smaller top up doses may optimize an individual's daytime exposure to drug while minimizing the dose. - This invention encompasses methods of preventing, attenuating, and/or treating motor disorder side effects in a patient with PD, including but not limited to, dyskinesia or other motor disorder, movement disorder, or motor or movement disorder side effects, that are associated with dopamine-related drugs, in addition to preventing, attenuating, and/or treating PD. In an embodiment, the methods involve therapeutic doses of a compound having agonist activity at both the 5-HT1a and 5-HT1b receptors, such as eltoprazine or a pharmaceutically acceptable salt thereof, and dosing regimens and combinations which optimally provide effective and lasting plasma concentrations of drug in a patient undergoing treatment.
- In an embodiment, the method comprises administering to a patient in need thereof a therapeutic dose of a compound having agonist activity at both the 5-HT1a and 5-HT1b receptors, or two separate compounds having agonist activity, one targeting the 5-HT1a receptor, and another compound targeting the 5-HT1b receptor. Optionally in combination with targeting the 5-HT1a and 5-HT1b receptors, the invention encompasses administering to the patient in need thereof a compound that targets the same, a similar, or a different drug pathway, one that is useful in treating L-DOPA-induced dyskinesia (LID) or other movement disorders or motor disorder side effects associated with dopamine-related drugs, one that is useful in treating PD, or one that is useful for treating both LID or other movement or motor disorders, or movement or motor disorder side effects associated with dopamine-related drugs and PD. This additional compound may also be useful such that the effective dose of L-DOPA or other dopamine-related drug that is necessary to treat PD is reduced. In some embodiments, the invention contemplates administering to the patient in need thereof L-DOPA, in addition to a compound that targets the same, a similar, or a different drug pathway, one that is useful in treating L-DOPA-induced dyskinesia (LID), one that is useful in treating PD, or one that is useful for treating both LID or other movement disorders or motor disorder side effects associated with dopamine-related drugs and PD.
- The dopamine-related drugs encompassed by the invention include drugs that increase the activity of the dopamine receptor, including dopamine agonists and partial agonists, whether acting directly or indirectly, as well as dopamine precursors, such as L-DOPA. In a preferred embodiment, the dopamine-related drug treatment is L-DOPA therapy. In other embodiments, the dopamine-related drug may be a dopamine receptor agonist, including, but not limited to bromocriptine, pergolide, cabergoline, apomorphine, and lisuride, or a non-ergoline dopamine agonist, including, but not limited to ropinirole or pramipexole.
- In yet other embodiments, the methods of the invention encompass preventing, attenuating, and/or treating any of the movement disorders, motor disorders, movement disorder side effects, or motor disorder side effects described herein, associated with dopamine-related drug treatments, or a combination of dopamine-related drug treatments, such as a combination of dopamine precursors, a combination of dopamine agonists or partial agonists, and a combination of one or more dopamine precursors and one or more dopamine agonists or partial agonists.
- Dopamine precursors such as L-DOPA are often administered with a DOPA decarboxylase inhibitor (DDCI) (also known as aromatic L-amino acid decarboxylase inhibitors (AAADI)). Non-limiting examples of such compounds contemplated by the invention include benserazide (Madopar, Prolopa, Modopar, Madopark, Neodopasol, and EC-Doparyl); carbidopa (Lodosyn, Sinemet, Parcopa, and Atamet); and Methyldopa (Aldomet, Aldoril, Dopamet, and Dopegyt). In addition to DDCIs, L-DOPA or other dopamine precursors are also often administered with compounds that inhibit the action of catechol-O-methyl transferase (COMT inhibitors). Non-limiting examples of COMT inhibitors for use in the methods herein include entacapone, tolcapone, and nitecapone.
- The methods of the invention encompass preventing, attenuating, and/or treating any of the movement or motor disorder side effects described herein associated with L-DOPA treatment, or treatment with another dopamine-related drug, L-DOPA treatment or other dopamine-related drug treatment in combination with DDCI (AAADI) treatment, L-DOPA treatment or other dopamine-related drug treatment in combination with COMT inhibitors, and L-DOPA treatment or other dopamine-related drug treatment in combination with DDCI (AAADAI) treatment and COMT inhibitors. In one embodiment, the methods of the invention encompass preventing, attenuating, and/or treating any of the motor disorder side effects described herein, associated with administering the combination of carbidopa, levodopa, and entacapone. In one embodiment, the combination of carbidopa, levodopa, and entacapone is administered as Stalevo.
- In an embodiment, the methods of the invention encompass preventing, attenuating, and/or treating PD itself, including the movement disorders associated with PD. In preferred embodiments, the compound having agonist activity at both the 5-HT1a and 5-HT1b receptors is eltoprazine or a pharmaceutically acceptable salt thereof. In an embodiment, the compound is eltoprazine hydrochloride.
- In an embodiment, the invention provides a method of prevention, attenuation, and/or treatment of movement or motor disorder side effects, including but not limited to dyskinesia, that are associated with L-DOPA therapy, such as LID, or other dopamine-related drugs in PD patients comprising administering to a patient in need thereof a therapeutic dose of a compound or a combination of two or more different compounds that acts/act as an agonist or partial agonist at the 5-HT1a receptor in a dosing regimen involving administering the compound or combination of compounds at certain dosing times and intervals.
- In another embodiment, this invention provides a method of prevention, attenuation, and/or treatment of movement or motor disorder side effects, including but not limited to dyskinesia, that are associated with L-DOPA therapy or other dopamine-related drugs in PD patients comprising administering to a patient in need thereof a therapeutic dose of a compound or a combination of two or more different compounds that acts/act as an agonist or partial agonist at the 5-HT1b receptor.
- In another embodiment, this invention provides a method of prevention, attenuation, and/or treatment of movement or motor disorder side effects, including but not limited to dyskinesia, that are associated with L-DOPA therapy or other dopamine-related drugs in Parkinson's patients comprising administering to a patient in need thereof a therapeutic dose of a compound or a combination of two or more different compounds that acts/act as an agonist or partial agonist at both the 5-HT1a and 5-HT1b receptors. When a single compound is used, this compound may act as an agonist or partial agonist at both the 5-HT1a and 5-HT1b receptors. When two or more different compounds are used, certain compounds may act at solely on one receptor (5-HT1a or 5-HT1b) and certain compounds may act at both receptors. In one embodiment, each compound acts solely on a particular receptor (5-HT1a or 5-HT1b) with the combination of compounds used resulting in the activity of both receptors. In another embodiment, at least one compound acts on both receptors. In another embodiment, all compounds act on both receptors.
- In one embodiment, this invention provides a method of prevention, attenuation, and/or treatment of movement or motor disorder side effects, including but not limited to dyskinesia or LID, that are associated with L-DOPA therapy or other dopamine-related drugs in Parkinson's patients comprising administering to a patient in need thereof a therapeutic dose of eltoprazine. In a preferred embodiment, the invention provides a method of preventing, attenuating, and/or treating Parkinson's disease, comprising administering to a patient in need thereof a dopamine-related drug and most preferably, L-DOPA, in combination with a therapeutic dose of eltoprazine or a pharmaceutically acceptable acid addition salt thereof.
- In some embodiments, the invention provides methods for treating one or more symptoms of Parkinson's disease. Examples of such symptoms include but are not limited to dyskinesia, hyperkinesia, speech changes, loss of facial expression, cognitive dysfunction, mood swings, emotional ability, euphoria, bipolar syndrome, anxiety, aphasia, dysphasia, or disturbances, dementia or confusion, depression, fear, anxiety, memory difficulties, slowed thinking, sexual dysfunction, fatigue, aching, and loss of energy.
- For all the conditions described herein, one of ordinary skill in the art will appreciate how to determine the presence or absence of characteristic symptoms and also how to diagnose these conditions. A number of criteria for diagnosing disease are useful for characterizing these conditions such as for example, NINCDS-ADRDA criteria (McKhann et al., 1984), the ICD-IO criteria (World Health Organization, 1992), and/or the DSM-IV criteria (American Psychiatric Association, 1994). Other manuals useful in diagnosing the conditions described herein include for example, but are not limited to Oppenheimer's Diagnostic Neuropathology: A Practice Manual (Esiri and Perl, 2006, Hodder Amold, London.); Harrison's Principles of Internal Medicine (Ed. Kasper et al, 16th Ed. 2005 McGraw Hill, Columbus, Ohio); Goetz: Textbook of Clinical Neurology (Eds. Goetz, Pappert, 2nd Ed. 2003, W.B. Saunders, Philadelphia, Pa.). One of ordinary skill will be aware of other such manuals routinely used in the art to diagnose these conditions.
- Eltoprazine (1-(2,3 -dihydro-1, 4-benzodioxanyl-5-yl) piperazine) is particularly preferred for use in the methods of the invention, including pharmaceutically acceptable salts thereof, and preferably HC1. Another preferred compound that may be useful for this invention is batoprazine, (8-(1-piperazine)-2H-1-benzopyran-2-one). This invention also includes the use of prodrugs of the compounds of the formulas provided, specifically derivatives of the compounds of the formulas that are inactive but are converted to an active form in the body following administration.
- Eltoprazine and processes for its synthesis are known in the art and is described in U.S. Pat. No. 4,833,142; U.S. Pat. No. 5,424,313; European Patent No. 189,612; and European Patent No. 138,280, each of which is incorporated herein by reference in its entirety. Eltoprazine is commercially available, for example, through Tocris Bioscience (Ellisville, Mo.).
- The invention encompasses many possible administration strategies including, but not limited to, administration of the 5-HT1a/1b receptor agonist or partial agonist before or after initiation of L-DOPA or other dopamine-related drug administration, and administration of the 5-HT1a/1b receptor agonist or partial agonist before or after development of motor disorder side effects. Dosage strategies include therapeutic and sub-therapeutic dosages of L-DOPA or other dopamine-related drug. In certain embodiments, this invention encompasses a reduction in the dosage of L-DOPA or other dopamine-related drug after administration of the 5-HT1a/1b receptor agonist or partial agonist. In instances where eltoprazine is used as the 5-HT1a/1b receptor agonist, non-limiting examples of daily dosages include from 3 mg to 30 mg; or 2.5 mg, 5.0 mg, 7.5 mg, and 10 mg as embodiments within the scope of the invention. Particularly preferred dosages of eltoprazine, in humans, are 5 mg/day and 7.5 mg/day, at one or more dosing intervals. Administration schedules may also be altered to achieve a therapeutically effective concentration of compound to treat the disorder or symptoms described herein. In some embodiments, for example, the compound may be administered once per day, twice per day, thrice per day, 4 times per day, 5 times per day, 7 times per day or 10 times per day.
- The methods of the invention embrace a number of newly determined, antidyskinetic dosing combinations and regimens involving eltoprazine to reduce LID and/or to optimize the daytime plasma concentration in the individual (human patient) undergoing treatment. In accordance with the present invention, doses of eltoprazine administered to a patient in need thereof in certain dosing schedules or regimens were surprisingly found to be effective in achieving maximal and desired plasma concentrations in the patient with lasting effects. By way of example, daily doses of eltoprazine of 5 mg to 10 mg, preferably 5 mg and 7.5 mg, resulted in a daytime plasma concentration in the range of 10 ng/ml to 30 ng/ml. In an embodiment, the plasma concentration range is 9 ng/ml or 17 ng/ml.
- In embodiment, the methods involve administering eltoprazine to a patient in need at a dose of 5 mg or 7.5 mg to effectively reduce dyskinesia, namely, LID. In embodiments, a daytime plasma concentration following eltoprazine administration is in the range of 10 to 30 ng/ml or in the range of 9 to 17 ng/ml. In particular embodiments, at a dose of 5 mg, the plasma concentration of drug (eltoprazine) is approximately 10 ng/ml, while at a dose of 7.5 mg, the plasma concentration of drug (eltoprazine) is approximately 17 ng/ml. The invention encompasses a variety of daily dosing combinations to achieve a desired and effective target daytime plasma concentration range. Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen.
- In an embodiment, the methods involve administering eltoprazine to a patient in need twice daily at four or six hour intervals with an eltoprazine dose of 2.5 mg, 5 mg, or 7.5 mg. In a particular embodiment, the dose is 5 mg. In another particular embodiment, the dose is 7.5 mg. In an aspect, dosing at four or six hour intervals may achieve optimal daytime plasma concentration in the individual from 10 AM to 8 PM, for example. See, e.g.,
FIG. 3 . Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen. - In an embodiment, the methods involve administering eltoprazine to a patient in need twice daily at four hour intervals with an eltoprazine dose of 2.5 mg, 5 mg, 7.5 mg, or 10 mg. In a particular embodiment, the dose is 5 mg. In another particular embodiment, the dose is 7.5 mg. In an aspect, eltoprazine doses of 5 mg and 7.5 mg may optimize the daytime plasma concentration, for example, from 10 AM to 8 PM. See, e.g.,
FIG. 4 . Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen. - In an embodiment, the methods involve administering eltoprazine to a patient in need three times daily at four hour intervals with an eltoprazine dose of 2.5 mg, 5 mg, or 7.5 mg. In a particular embodiment, the dose is 5 mg. In another particular embodiment, the dose is 7.5 mg. In an aspect, three daily doses of eltoprazine, such as a 5 mg dose and a 7.5 mg dose, may allow maximal plasma concentrations to be achieved, for example, in the late afternoon evening period, extending into the night time, thus providing longer term reduction in the patient's symptoms. See, e.g.,
FIG. 5 . Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen. - In another embodiment, the methods involve administering a loading dose of eltoprazine to a patient in need, followed by a subsequent dose at a predetermined time thereafter. More particularly, a dose of eltoprazine is administered early in the day, such as a morning loading dose, followed by another dose at a later interval, such as at midday. In embodiments, the subsequent, ‘top up’ dose may be administered one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, etc. hours, and intervals there between, after the initial loading dose. By way of example, the subsequent dose may be administered from one to twelve hours after the loading dose; or from two to ten hours after the loading dose; or from two to six hours after the loading dose, etc., A total daily dose of eltoprazine may be 10 mg or 15 mg. Such a regimen involving a loading dose followed by one or more smaller, ‘top up’ doses, may optimize daytime exposure while minimizing the overall dose administered to the individual. See, e.g.,
FIG. 6 . In an embodiment, an individual in need is dosed with a 7.5 mg loading dose of eltoprazine, followed by a 2.5 mg dose of eltoprazine thereafter. In an embodiment, an individual in need is dosed with a 7.5 mg loading dose of eltoprazine, followed by a 5 mg dose of eltoprazine thereafter. In an embodiment, an individual in need is dosed with a 10 mg loading dose of eltoprazine, followed by a 5 mg dose of eltoprazine thereafter. In an embodiment, an individual in need is dosed with a 10 mg loading dose of eltoprazine, followed by a 2.5 mg dose of eltoprazine thereafter. Oral dosing and administration of eltoprazine are embraced by this dosing combination and regimen. - In embodiments related to oral dosing of eltoprazine and the dosing regimens herein described, the oral dosage form is not intended to be limiting and thus may include liquid oral dosing forms and solid oral dosage forms, such as pills, capsules, or tablets. Multilayered tablets, such as bi-layered and tri-layered tablets are encompassed by the invention. Without limitation, controlled release, sustained release, delayed release and extended release solid oral dosage forms are encompassed by the invention.
- In accordance with the methods, eltoprazine and/or a related compound(s) is administered in combination with one or more additional compound(s). The additional compound(s) may have actions that are similar to, synergistic to, or different than eltoprazine and/or its related compound(s). Non-limiting examples of additional compounds and drugs that may be administered in combination with eltoprazine may be found, for example and without limitation, in U.S. Pre-Grant Publication No. US 2013/0331399, the contents of which are incorporated by reference herein in their entirety. In an embodiment, eltoprazine and/or a related compound(s) is administered optionally in combination with one or more additional compound(s) for prevention, attenuation, and/or treatment of dyskinesia or other movement or motor disorder or side effect thereof that is associated with L-DOPA therapy or other dopamine-related drugs in Parkinson's patients. In another embodiment, eltoprazine and/or a related compound(s) is administered optionally in combination with one or more additional compound(s) for prevention, attenuation, and/or treatment of PD.
- In yet another embodiment, L-DOPA is administered to a PD patient in need thereof, and following this administration, by the methods described herein, eltoprazine and/or a related compound(s) is administered. The eltoprazine and/or a related compound(s) is administered optionally in combination with one or more additional compound(s) for prevention, attenuation, and/or treatment of dyskinesia that is associated with L-DOPA therapy. In yet another embodiment, L-DOPA is administered to a PD patient in need thereof following the administration of eltoprazine and/or a related compound(s) optionally in combination with one or more additional compound(s), for prevention, attenuation, and/or treatment of dyskinesia that is associated with L-DOPA therapy.
- In yet another embodiment, L-DOPA is administered to a PD patient in need thereof, and following this administration, by the methods described herein, eltoprazine and/or a related compound(s) is administered after the development of motor side effects, optionally in combination with one or more additional compound(s), for prevention, attenuation, and/or treatment of dyskinesia that is associated with L-DOPA therapy.
- In yet another embodiment, L-DOPA is administered to a PD patient in need thereof, and following this administration, by the methods described herein, eltoprazine and/or a related compound(s) is administered prior to the development of motor side effects, optionally in combination with one or more additional compound(s), for prevention, attenuation, and/or treatment of dyskinesia that is associated with L-DOPA therapy.
- In one embodiment, the invention is not used for prevention, attenuation, and/or treatment of the associated cognitive impairment in PD. In another embodiment, the invention is not used for prevention, attenuation, and/or treatment of any one or more of the following: Alzheimer's disease, Huntington's disease, Cushing's syndrome, Lewy body disease, multiple sclerosis, stroke, addictive disorders, pervasive development disorder, Fragile X syndrome, anxiety disorders, Prader-Willi Syndrome, schizophrenia, bipolar disorder, depressive disorders, vascular dementia, mild cognitive impairment, dementia, or delirium. In an alternative embodiment, the invention may be used for prevention, attenuation, and/or treatment of one or more of these disorders.
- In one embodiment, the methods of the invention encompass preventing, attenuating, and/or treating a movement or motor disorder, or a movement or motor side effect associated with a dopamine-related drug for the treatment of PD, which is not L-DOPA.
- In some embodiments, the invention encompasses preventing, attenuating, and/or treating in patients with PD, movement disorders, motor disorders or side effects thereof associated with dopamine-related drugs, in addition to preventing, attenuating, and/or treating PD, by administering to a patient in need thereof a therapeutic dose of a compound having agonist activity at both the 5-HT1a and 5-HT1b receptors, or two separate compounds having agonist activity, one targeting the 5-HT1a receptor, and another compound targeting the 5-HT1b receptor, in combination with deep brain stimulation as performed in a surgical procedure, or in combination with magnetic brain stimulation, such as transcranial magnetic stimulation. In one embodiment, the invention encompasses preventing, attenuating, and/or treating in patients with PD, movement disorders, or motor disorder side effects associated with dopamine-related drugs, in addition to preventing, attenuating, and/or treating PD, by administering to a patient in need thereof a therapeutic dose of eltoprazine in combination with deep brain stimulation and/or transcranial magnetic stimulation, and optionally in combination with any other compound described herein. Any order of treatment found to be beneficial is contemplated by the invention. For example, the deep brain stimulation and/or transcranial magnetic stimulation may precede the dopamine-related drug treatment, may follow the dopamine-related drug treatment, may precede the eltoprazine treatment, or may follow the eltoprazine treatment.
- The doses of the compounds used in treating the disorders described herein in accordance with this invention will vary in the usual way with the seriousness of the disorder, the weight, and metabolic health of the individual in need of treatment. The methods of the invention provide therapeutically effective doses and treatment schedules for administration to individual patients to arrive at the desired therapeutic or prophylactic effect, including a desired plasma concentration, while minimizing side effects. Particularly beneficial doses of eltoprazine for providing a more sustained effect include a 5 mg dose and a 7.5 mg dose. In a preferred embodiment, the 5 mg and the 7.5 mg doses of eltoprazine are administered to a patient three times daily. In another preferred embodiment, the 5 mg and the 7.5 mg doses of eltoprazine are administered to a patient three times daily at four hour intervals.
- Administration schedules may also be altered to achieve other therapeutically effective concentrations of compound to treat the disorders or symptoms described herein.
- The methods described herein reflect the discovery of particular efficacious doses of eltoprazine and dosing schedules that achieve plasma concentrations in treated individuals for reducing and/or treating levodopa-induced dyskinesia in Parkinson's patients. The particularly efficacious doses and schedules are 5 mg and 7.5 mg of eltoprazine administered two or three times per day at four hour intervals, for example, as shown in
FIGS. 4 and 5 herein. Example 1 andFIG. 2 also show that administration of eltoprazine to Parkinson's patients already on levodopa treatment who then receive eltoprazine do not show a reduction in the efficacy of levodopa therapy for treating PD. Further, eltoprazine was well-tolerated, and there were no serious adverse events from administration. - In some embodiments, eltoprazine and/or related compounds may be administered once per day, twice per day, thrice per day, 4 times per day, 5 times per day, 7 times per day or 10 times per day. In preferred embodiments, eltoprazine is administered one, two, or three times per day. Often the dosage is divided equally throughout the day, however in some embodiments to treat certain disorders or symptoms, it may be useful to bias the dosage administration schedule so that most of the daily treatment is administered at the beginning half or portion of the day. In some embodiments, about 50%, 60%, 70% or 80% of the dosage is administered in the first half or portion of the day. In other embodiments, it may be more appropriate to administer most of the dosage in the latter half or portion of the day so that about 50%, 60% , 70% or 80% of the dosage is administered in the latter half or portion of the day.
- The 5-HT1a/1b receptor agonist, partial agonist, or agonists and, optionally, at least one additional compound, may be administered before, concurrently, or after administration of L-DOPA or other dopamine-related drug. In one embodiment, the 5-HT1a/1b receptor agonist, partial agonist, or agonists and, optionally, at least one additional compound, is administered before administration of L-DOPA or other dopamine-related drug. In one embodiment, after administration of the 5-HT1a/1b receptor agonist, partial agonist, or agonists and, optionally, at least one additional compound, the dose of L-DOPA or other dopamine-related drug is reduced. The 5-HT1a/1b receptor agonist, partial agonist, or agonists may be administered before, concurrently, or after administration of at least one additional compound.
- The 5-HT1a/1b receptor agonist, partial agonist, or agonists and, optionally, at least one additional compound, may be administered before, concurrently, or after onset of symptoms. In one embodiment, the symptoms include a movement or motor disorder, or a movement or motor disorder side effect from the use of L-DOPA or other dopamine-related drugs. In one embodiment, the 5-HT1a/1b receptor agonist and, optionally, at least one additional compound, is/are administered after the development of a movement or motor disorder side effect. In one embodiment, the 5-HT1a/1b receptor agonist, partial agonist, or agonists and, optionally, at least one additional compound, is/are administered before the development of a movement or motor disorder side effect.
- Administration of the compounds of this invention may be by any method used for administering therapeutics, such as for example, oral, parenteral, intravenous, intramuscular, subcutaneous, rectal, or topical administration, such as through the use of a transdermal patch. In a particular embodiment, eltoprazine is orally administered to a patient in need.
- It will be appreciated by one of ordinary skill in the art that age of the patient with the conditions described herein may respond to treatment at different degrees depending on factors such as dosage or administration or the presence of other factors or co-morbid conditions. Therefore, one of ordinary skill in the art will appreciate that the methods described herein may be directed to a particular age group.
- In addition to comprising the therapeutic compounds for use in this invention, especially eltoprazine [1-(2,3-dihydro-1, 4-benzodioxin-5-yl) piperazine] or pharmaceutically acceptable salts (preferably HCl in the case of eltoprazine) or pro-drug thereof, the pharmaceutical compositions for use with this invention may also comprise a pharmaceutically acceptable carrier. Such carriers may comprise additives, such as preservatives, excipients, fillers, wetting agents, binders, disintegrants, buffers may also be present in the compositions of the invention. Suitable additives may be, for example magnesium and calcium carbonates, carboxymethylcellulose, starches, sugars, gums, magnesium or calcium stearate, coloring or flavoring agents, and the like. There exists a wide variety of pharmaceutically acceptable additives for pharmaceutical dosage forms, and selection of appropriate additives is a routine matter for those skilled in art of pharmaceutical formulation.
- The compositions for use in the methods may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions.
- In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose. Unit dose forms for oral administration may be tablets, capsules, and the like, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; and carriers or fillers, for example, lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine. Additives may include disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycolate or microcrystalline cellulose; preservatives, and pharmaceutically acceptable wetting agents such as sodium lauryl sulfate.
- In addition to unit dose forms, multi-dosage forms are also contemplated to be within the scope of the invention. Modified or controlled release dosage forms are contemplated for use in the invention, including, but not limited to, controlled release dosage forms, sustained release dosage forms, extended release dosage forms, delayed release dosage forms, and pulsatile release dosage forms.
- In an embodiment, the 5-HT1a/1b receptor agonist, such as eltoprazine or a pharmaceutically acceptable salt thereof, is administered in an oral solid dosage form. The oral solid dosage form may be a pill, capsule, caplet, or tablet. In an embodiment, eltoprazine is administered in the form of a multi-layered tablet, such as a bi-layered or a tri-layered tablet. The methods encompass the administration of eltoprazine as the active ingredient in a bi- or tri-layered oral solid dosage form as a single daily dose, as described herein.
- Suitable polymers for use in the controlled release formulations of the present invention include, but are not limited to uncrosslinked, linear polymers including cellulosic polymers, preferably hydroxyethyl cellulose, sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose and hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, and ethyl cellulose, and combinations thereof; covalently crosslinked insoluble polymers such as high molecular weight crosslinked homopolymers and copolymers of (meth) acrylic acid including carbopol resins, or mixtures of these uncrosslinked and covalently crosslinked polymers. Additionally suitable polymers include acrylic acid, methacrylic acid, methyl acrylate, ammonio methylacrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate, vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, polyvinylacetate phthalate, vinylacetate crotonic acid copolymer, and ethylene-vinyl acetate copolymers, to name a few. Various combinations of two or more of the above polymers are also contemplated for use in the dosage forms of the invention.
- Delayed release compositions may be prepared, for example, by employing slow release coatings, micro encapsulation, and/or slowly dissolving polymers.
- The solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, for example, with an enteric coating.
- Multilayered tablets may be produced by processes and procedures known and available in the art. See, e.g., EP 1681051 and EP 2517696 A1, as relates to the following. In some cases, the tablet comprises multiple layers having different time release profiles. The tablet may have two, three, four or five layers, in which, for example, the first layer is formulated for immediate release and the second layer is formulated for delayed release. In embodiments having a third layer, the third layer may be formulated to have a release that is later than the second layer. In some embodiments having a third layer, the third layer is located in the middle of the tablet. In other embodiments having multiple layers, the layers having the longest delay are formulated to be nearest the center of the multi-layer tablet, either in horizontal layers, or in the form of a core coated by subsequent layers.
- In certain embodiments comprising a layer formulated for immediate release, such a layer is formulated with one or more rate-controlling polymers and pharmaceutically acceptable excipients generally known in the art for immediate release. In certain embodiments comprising a layer formulated for delayed release, such a layer is formulated with one or more rate-controlling polymers and pharmaceutically acceptable excipients generally known in the art for immediate release. In certain embodiments of a delayed release layer, the rate-controlling polymer is a polyethylene oxide polymer. The molecular weight of the polyethylene oxide molecule of the polyethylene oxide polymer used may be 7,000,000 g/mole and Brookfield viscosity of its 1% m/v aqueous solution at 25° C. is 7500-10000 cps (Colorcon-Sentry Polyox WSR 303-Leo-NF-Dow).
- In certain embodiments, the tablet developed is composed of two layers, with one of the layers providing immediate release, and the other layer providing extended release. By way of example, 65-85% of the active ingredient (API) content of the tablet may be present at the extended release providing layer and 15-35% may be present at the immediate release providing layer. The two separate layers may be compressed as two layer tablet. In another embodiment, the layer providing extended release forms the tablet core and the layer providing immediate release is coated on the tablet core. In another exemplary embodiment of a two layer tablet, the immediate release layer provides extended release between 20% to 40% in the first hour in order to provide the adequate effective blood level and two-phase pellets to achieve Cmax value. Thereafter, in in order to keep the plasma concentration of the active ingredient effective in the long run, it provides 8-hour and longer term release of the remaining active ingredient amount. In a dissolution test, 20% to 40% of the active ingredient is released in the first hour at 0.1 N HCl medium. The other part of the composition provides 5% to 12% release per hour in pH 6.8 phosphate buffer.
- Excipients known in the art may be used to formulate the extended release providing layer, including, but not limited to, calcium phosphate dibasic as buffer agent, talc and magnesium stearate as lubricant and colloidal silicon dioxide (Aerosil 200) as glidant. Excipients known in the art may be used to formulate the immediate release providing layer, including, but not limited to, microcrystalline cellulose as diluent and binder, croscarmellose sodium as disintegrant, magnesium stearate as lubricant and colloidal silicon as glidant.
- Rate controlling polymers employed in multi-layered tablet forms containing one or more active ingredients may be one or more of hydrophilic polymers, hydrophobic polymers or a combination thereof. The one or more rate-controlling polymers may comprise about 5% to about 60% w/w of the tablet. Hydrophilic polymers in multi-layer tablet forms may be one or more of cellulose derivatives comprising hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose or combinations thereof; polyvinylpyrrolidone, vinyl acetate/vinyl-pyrrolidone copolymer, microcrystalline cellulose, polysaccharides, polyalkylene glycols, starch and derivatives thereof. The hydrophobic polymers in multi-layer tablet forms may be one or more of ethyl cellulose, cellulose acetate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, poly (alkyl) methacrylate, and copolymers of acrylic or methacrylic acid esters, waxes, shellac and hydrogenated vegetable oils. The layers may be prepared by one or more of dry granulation, wet granulation or direct compression. The layer containing the active ingredient may further include an alkalizing agent. The tablet may further include one or both of an outer protective coating layer or a separating layer between first and second layers. The tablet may exhibit a Tmax of one active which occurs at a time 4 hours to about 10 hours and exhibits a Tmax of another active which occurs at a
time 5 hours to about 18 hours after administration of the tablet to a human patient. See, e.g., WO 2006092711 A2. - Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, and hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil or fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavoring or coloring agents.
- For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved in water or saline for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, additives such as a local anesthetic, preservative and buffering agent can be dissolved in the vehicle. Suitable buffering agents are, for example, phosphate and citrate salts. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by conventional means, for example by exposure to radiation or ethylene oxide, before being suspended in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- The 5-HT1a/1b receptor agonist, partial agonist, or agonists and, optionally, at least one additional compound may be provided in a kit. In one embodiment, a kit may comprise at least one 5-HT1a/1b receptor agonist, partial agonist, or agonists, and at least one additional compound. In one embodiment, a kit may comprise at least one 5-HT1a/1b receptor agonist, partial agonist, or agonists, L-DOPA or other dopamine-related drug, and optionally at least one additional compound, such as set forth, for example, in U.S. Pre-Grant Publication No. US 2013/0331399, the contents of which are incorporated by reference herein in their entirety. In an embodiment, the kit may also include instructions for administration of the compounds. In one embodiment, the kit is intended for use by a subject having PD. In another embodiment, a kit may comprise at least one 5-HT1a/1b receptor agonist, partial agonist, or agonists, at least one dopamine precursor, at least one DDCI, and instructions for administering the compounds. In another embodiment, a kit may comprise at least one 5-HT1a/1b receptor agonist, partial agonist, or agonists, at least one dopamine precursor, at least one DDCI, at least one COMT inhibitor, and instructions for administering the compounds. In an embodiment, the at least one 5-HT1a/1b receptor agonist is eltoprazine.
- All patents and patent publications referred to herein are hereby incorporated by reference.
- Certain modifications and improvements will occur to those skilled in the art upon a reading of the foregoing description. It should be understood that all such modifications and improvements have been omitted herein for the sake of conciseness and readability but are properly within the scope of the following claims. It is understood that the following examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggestive to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.
- This example describes a multicenter, randomized, double-blind, placebo-controlled, dose finding study of oral eltoprazine in Parkinson's patients with L-DOPA induced dyskinesias, in a levodopa challenge-dose setting in Parkinson's Disease. A total of 22 patients participated in the study, out of which 18 patients fulfilled the protocol in terms of eligibility, interventions, and outcome assessment.
- Subjects had to meet all of the following criteria to be eligible for the study:
- 1. Each patient had Parkinson's disease, defined according to the UK Brain Bank Criteria (see Hughes et al., J Neurol Neurosurg Psychiatry, 1992. 55(3): p. 181-4; Lees et al., Lancet, 2009. 373: p. 2055-66). Bradykinesia symptoms were combined with one of resting tremor, rigidity or postural imbalance.
2. Each patient had been treated for at least 3 years with L-DOPA prior to this study.
3. Each patient had significant dyskinesias after L-DOPA dosages according to clinical experience.
4. Each patient had significant dyskinesias after the administration of a single challenge dose of L-DOPA using two dyskinesia rating scales. The screening test was performed with a challenge dose of 150% of the normal regular dose of L-DOPA. If no dyskinesias was present during the first challenge, the challenge was repeated on an alternate day (and) significant dyskinesias in a patient self-administered diary with 3 levels with 3 grades (“off,” “on without dyskinesias,” “on with hyperkinesias”) after the challenge dose has been given. Patients were included if one of the two challenge tests were positive and diary was positive for dyskinesias. In addition to the observed types of dyskinesias (dystonia, hyperkinesias), a temporal patterns were described as “peak-of dose,” “end-of-dose dyskinesias” and “bi-phasic dyskinesias.” Quantification was made by “peak-of-dose” ratings and area-under-the-curve (AuC) of scores.
5. Each patient was over 18 years of age.
6. This inclusion criterion applied to females of child-bearing potential (not surgically sterilized and between menarche and 1 year postmenopausal) only. Each female patient tested negative for pregnancy at the time of enrollment based on a serum pregnancy test and agreed to use a reliable method of birth control during the study.
7. Each patient signed informed consent.
8. Each patient had to able to communicate effectively with the investigator and study coordinator. - The presence of any of the following conditions excluded a subject from the study:
- 1. Exclusion criteria for Parkinson's disease according to the UK Brain Bank Criteria for Parkinson's disease.
2. Fulfillment of any other atypical parkinsonism diagnosis according to published criteria for multiple system atrophy (see Gilman, S., et al., Neurology, 2008. 71(9): p. 670-6), progressive supranuclear paresis (see Litvan, I., et al., Neurology, 1996. 47(1): p. 1-9), dementia with Lewy body (see McKeith, I. G., et al., Neurology, 2005. 65(12): p. 1863-72), corticobasal gangliotic disease (see Litvan, I., et al., J Neuropathol Exp Neurol, 1996. 55(1): p. 97-105), and dementia with Parkinson's disease (see Emre, M., et al., Mov Disord, 2007. 22(12): p. 1689-707; quiz 1837).
3. Any suspected secondary parkinsonism; drug induced parkinsonism; toxin-induced parkinsonism; trauma-induced parkinsonism; normal pressure hydrocephalus and vascular parkinsonism.
4. Ongoing treatment with any selective serotonin re-uptake inhibitors (SSRI) or any combined serotonin-norepinephrine re-uptake inhibitors (SNRT) 4 weeks prior to the study.
5. Ongoing treatment with anti-parkinsonism medications (Cabergoline; Duodopa infusion; ApoGo infusion; Amantadine; Memantine if used against dyskinesias), and other medication with the potential for drug-interactions.
6. Significant depression defined as >18 in the Montgomery Asberg Depression Rating Scale combined with a clinical evaluation as to any clinical relevant depression.
7. Pregnant or breast-feeding.
8. Reduced kidney function; defined as a creatinine level>120 μmol/L.
9. Reduced liver function, defined as aspartate aminotransferase, ASAT>1.0 μkat/L or alanine aminotransferase, ALAT>1.0 μkat/L or glutamyl transpeptidase, GT>1.6 μkat/L, or total bilirubin>30 μmol/L, or alkaline phosphatase, ALP>6.0 μkat/L.
10. History of any other medical condition thought to interfere with the study or study medication (i.e., recent myocardial infarction, uncontrolled diabetes, uncontrolled hypertension (systolic blood pressure>180 mmHg), ongoing severe infection).
11. Receipt of an investigational drug within 30 days or 5 half-lives of the drug, whichever is longer, prior to entering this study.
12. Any known allergy to eltoprazine or the constituents of the study medication and the placebo capsules.
13. Any indication that patients are unsuitable in any other way to participate in this study, in the opinion of the investigator. - This study also assessed the safety and tolerability of eltoprazine in adults with Parkinson's Disease using the following measures: a) population mean values for the change in dyskinesia ratings between the placebo and screening baseline values and any of the eltoprazine dosages used, calculated as the peak-effect on CDRS of any study medication; b) population mean values for the change in dyskinesia ratings between the placebo and screening baseline values and any of the eltoprazine dosages used, calculated as the AuC on Rush DRS of any study medication; c) any changes in the UPDRS-III total score; d) any change in the diary data set, between the baseline and placebo and any of the three study medication tests; e) any deterioration of the HADS scores after study medication compared with placebo; f) any development of depression over the course of the study period, determined by the Montgomery Asberg Depression Rating Scale (MADRS) and clinical judgment; g) comparison between the effects on Rush Dyskinesia Rating Scale (DRS) and Clinical Dyskinesia Rating Scale (CDRS) Area under the Curve (AuC) and peak of dose effects for the three study medication dosages.
- The study consisted of 7 visits, described below: a screening visit, five treatment visits, and one end-of-study visit.
- During the first visit, patients underwent screening for inclusion/exclusion criteria and safety assessments. Symptoms of parkinsonism, depression, and anxiety were assessed, and screening for significant L-DOPA dyskinesias were conducted using a challenge dose (150%) of L-DOPA. Subjects who were taking a prohibited medication were required to complete a washout period of appropriate length, as determined by the investigator. All patients received challenge doses (150%—up to a maximum of 250 mg) of L-DOPA at screening and at each treatment visit. L-DOPA was administered as Sinemet (L-DOPA combined with carbidopa in a fixed ratio of 4:1, unless a patient has a known allergy or intolerance to this drug). If a patient is intolerant to Sinemet, an equivalent dose of Madopar Quick could be used. There was an observation period of 3 hours (6×30 min, or 180 minutes) after dosing.
- During each of five visits, and after a two-hour fast, each patient received a challenge dosage (150%—up to a maximum of 250 mg) of levodopa. Additionally, during each of the five treatment visits, patients were also treated with single dose treatments of oral capsules of three active study medication dosages (2.5 mg, 5 mg, or 7.5 mg of eltoprazine) or two placebo doses. The patients were periodically recorded for 180 minutes after treatment, and the videos were evaluated in a blinded manner.
- Visit 2 occurred within 30 days of
visit 1, and visits 3-6 followed one week apart from each other. - During the final visit or early termination visit, symptoms of parkinsonism, depression, anxiety, and L-DOPA dyskinesias were assessed, to capture any eltoprazine-related treatment effects on the degree of parkinsonism and any change in mood-related symptoms. Safety assessments were also conducted. A patient diary completed prior to and after the study period was used to evaluate any changes in perceived dyskinesias by the patients. A two-three day diary with 3 symptom lines—“off,” “on (normal),” “on with dyskinesias” were filled out by each patient between the screening and enrollment visits and in between
visits 2 through 6 to evaluate any changes in perceived dyskinesia by the patients. - The final visit, 7, was scheduled 4 days after visit 6. All study visits occurred within a ±5-day window of the time points noted above.
- After screening, each patient participated in the study for approximately 6-10 weeks. The duration of the study was about 30 weeks. Safety evaluations were based on reports of adverse effects, concomitant therapy, clinical laboratory results, medical history, physical examination, and vital signs. Patient videos were used to assess efficacy. Rating scales include UPDRS, CDRS, and Rush DRS. In addition, patient diaries were used for self-assessment of dyskinesia.
- The term “Unified Parkinson's Disease Rating Scale-III” and “UPDRS-III” refer to a standardized tool used to measure Parkinson's Disease severity, as described by Fahn et al., in Recent Developments in Parkinson's Disease, Fahn et al. (eds.) Plurham Park, N.J.: Macmillian Healthcare Information, 2:153-163,1987.
- The term “Clinical Dyskinesia Rating Scale” and “CDRS” refer to a modified abnormal involuntary movement scale (AIMS) allowing for independent rating of limbs, trunk, head/neck and face rated during the UPDRS movements. This scale can simultaneously rate dystonia and dyskinesias, as described by Goetz et al., in Movement Disorders, Vol. 9, No. 4, 1994, 390-394.
- The term “Rush Dyskinesia Rating Scale” and “Rush DRS” refer to an observer-based rating scale based on fixed movements. The numerical parts of the Rush DRS are recorded separately from the descriptive parts, as described by Goetz et al., in Movement Disorders, Vol. 9, No. 4, 1994, 390-394.
- The term “Hospital Anxiety & Depression Scale” and “HADS” refer to rating scales commonly used by doctors to determine the levels of anxiety and depression that a patient is experiencing, as described by Zigmond et al., in Acta Psychiatrica Scandinavica 67 (6): 361-370.
- The term “Montgomery-Åsberg Depression Rating Scale” and “MADRS” refer to an observer based ten-item diagnostic questionnaire used by psychiatrists to measure the severity of depressive episodes in patients with mood disorders, as described by Montgomery et al., in British Journal of Psychiatry 134 (4): 382-89.
- Patients presenting clinically with motor disorder side effects associated with L-DOPA therapy, including dyskinesia, were evaluated using the United Parkinson's Disease Rating Scale III (Recent Developments in Parkinson's Disease, vol. 2, Fahn et al. editors, Macmillan Publishing Co. Inc, 1987), an art-recognized dyskinesia severity scale (Marconi et al., Mov Disord, 9:2-12, (1994)). Briefly, the dyskinesia severity scale rates abnormal movements from 0 (none) to 4 (severe with markedly impaired function) in six different parts of the body (face, neck, and trunk, and four limbs).
- Filming occurred 30 minutes prior to, and every 30 minutes up to 180 minutes after a challenge test of L-DOPA and study medication. Approximately 5 minutes of video filming were performed each time. The “UPRDS movements” in the UPDRS scale was performed (arms in different positions, repeated pronations-supinations of the wrists, finger tapping of opposing fingers, opening and closing of the fists, foot stamping, raising from the chair, walking with a turn and a balance test). Each patient also performed tasks for the “Dyskinesia Rating Scales.” The same sequences were repeated prior to any challenge dose, and after every 30 minutes up to 180 minutes after the intake of the medications, for a total of 7 sequences. Each sequence was rated by two independent blinded raters using UPDRS, CDRS and Rush DRS. Videotaped records of each sequence were assessed by separate individual qualified raters at both of the two clinical centers.
- During screening, patients were asked to perform a self-administered rating of their dyskinesias by using a diary with 3 levels with 3 grades (“off,” “on without hyperkinesias,” and “on with hyperkinesias”). On the days following screening, the patients self-rated their symptoms over three days. A two day diary with 3-symptom lines (“off,” “on,” “on with dyskinesias”) was filled out by patients between the screening and enrollment visits and in between the
Visits 2 through 6 (one day before dosing and one day after dosing). - Analyses were done on both the intention-to-treat (ITT) and per protocol (PP) population, if applicable. The change between test sessions of the highest observed Unified Parkinson's Disease Rating Scale-III (UPDRS) within each session will be calculated between the randomized placebo test session and each active test session and will be analyzed with Wilcoxon Signed Rank test on the ITT population.
- The change in Mean AUC0-3 hours of CDRS ratings will be analyzed between the randomized Placebo Test session and each active Test session with Wilcoxon Signed Rank test on the ITT population. Changes to all secondary variables between the randomized placebo test session and each active test session were analyzed using Wilcoxon Signed Rank test on both ITT- and PP-population.
- Statistical analyses demonstrated that eltoprazine administered to Parkinson's disease patients with levodopa-induced dyskinesia (LID), statistically significantly reduced LID at both the 5 mg dose (p=0.0007) and the 7.5 mg dose (p=0.0467), as compared to placebo, when measured by the CDRS scale (See,
FIG. 1 ). In addition, eltoprazine administration at these doses did not affect L-DOPA efficacy, as measured by the UPDRS score (See,FIG. 2 ); both the 5 mg and 7.5 mg doses were statistically significant as compared to placebo). At the 5 mg dose, eltoprazine reduced LID in PD patients statistically significantly—as measured by the Rush Scale AUC. - In addition to its beneficial antidyskinetic effects, eltoprazine was well tolerated in this study, as there were no serious adverse events and normal motor responses to L-DOPA were not altered.
- All references, including patent applications and publications cited herein, are incorporated by reference in their entirety and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.
Claims (35)
1. A method of treating a movement or motor disorder side effect associated with administration of levodopa to a patient having Parkinson's disease, the method comprising:
administering to said patient in need of treatment a dose of eltoprazine or a pharmaceutically acceptable acid addition salt thereof to reduce said movement or motor disorder side effect, wherein said eltoprazine is administered at a dose of 5 mg or 7.5 mg two or three times per day.
2. The method according to claim 1 , wherein said movement or motor disorder side effect is dyskinesia or levodopa-induced dyskinesia.
3. The method according to claim 1 or claim 2 , wherein said eltoprazine is administered at a dose of 5 mg two times daily.
4. The method according to claim 1 or claim 2 , wherein said eltoprazine is administered at a dose of 5 mg three times daily.
5. The method according to claim 1 or claim 2 , wherein said eltoprazine is administered at a dose of 7.5 mg two times daily.
6. The method according to claim 1 or claim 2 , wherein said eltoprazine is administered at a dose of 7.5 mg three times daily.
7. The method according to any one of claims 1 to 6 , wherein said eltoprazine is administered at four, six, eight and twelve hour intervals.
8. The method according to any one of claims 1 to 6 , wherein said eltoprazine is administered at four or six hour intervals.
9. The method according to claim 8 , wherein said eltoprazine is administered at four hour intervals.
10. The method according to claim 1 or claim 2 , wherein said eltoprazine is administered at a loading dose, followed by administration of a subsequent dose at a predetermined time thereafter.
11. The method according to claim 10 , wherein said eltoprazine is administered at a loading dose of 7.5 mg, followed by administration of a subsequent dose of 2.5 mg at from two to twelve hours thereafter.
12. The method according to claim 10 , wherein said eltoprazine is administered at a loading dose of 7.5 mg, followed by administration of a subsequent dose of 2.5 mg at from two to six hours thereafter.
13. The method according to any one of claims 1 to 12 , wherein said patient is human.
14. The method according to any one of claims 1 to 13 , wherein said eltoprazine administration does not reduce efficacy of said levodopa administration.
15. A method of treating Parkinson's disease in a human in need thereof, the method comprising
administering to said human a dose of levodopa and a dose of eltoprazine or a pharmaceutically acceptable acid addition salt thereof, wherein said eltoprazine is administered at a dose of 5 mg or 7.5 mg two or three times per day.
16. The method according to claim 15 , wherein said eltoprazine and said levodopa are concurrently active in said human.
17. The method according to claim 15 or claim 16 , wherein said eltoprazine is administered to the human before said human develops dyskinesia associated with said levodopa administration.
18. The method according to claim 15 or claim 16 , wherein said eltoprazine is administered to said human after said human develops dyskinesia associated with said levodopa administration.
19. The method according to claim 15 or claim 16 , wherein said eltoprazine is administered to the human before the administration of said levodopa.
20. The method according to any one of claims 15 to 19 , wherein said eltoprazine is administered at a dose of 5 mg two times daily.
21. The method according to any one of claims 15 to 19 , wherein said eltoprazine is administered at a dose of 5 mg three times daily.
22. The method according to any one of claims 15 to 19 , wherein said eltoprazine is administered at a dose of 7.5 mg two times daily.
23. The method according to any one of claims 15 to 19 , wherein said eltoprazine is administered at a dose of 7.5 mg three times daily.
24. The method according to any one of claims 15 to 23 , wherein said eltoprazine is administered at four, six, eight and twelve hour intervals.
25. The method according to any one of claims 15 to 23 , wherein said eltoprazine is administered at four or six hour intervals.
26. The method according to claim 25 , wherein said eltoprazine is administered at four hour intervals.
27. The method according to any one of claims 1 to 26 , wherein said eltoprazine is orally administered.
28. The method according to claim 27 , wherein said eltoprazine is administered in a controlled release, sustained release, extended release, delayed release, or pulsatile release solid oral dosage form.
29. The method according to claim 28 , wherein the solid oral dosage form is a multi-layered tablet dosage form.
30. The method according to claim 29 , wherein the solid oral dosage form is a bi-layered or tri-layered tablet dosage form.
31. The method according to claim 30 , wherein the bi-layered or tri-layered tablet dosage form is a controlled release, sustained release, extended release, or delayed release oral dosage form.
32. The method according to any one of claims 1 to 14 , wherein the movement or motor disorder side effect associated with administration of levodopa is L-DOPA induced dyskinesia (LID).
33. The method according to any one of claims 15 to 26 , wherein L-DOPA induced dyskinesia (LID) is treated in the human.
34. The method according to any one of claims 1 to 33 , wherein, following eltoprazine administration, plasma concentration of the subject is in the range of 10 ng/ml to 30 ng/ml.
35. The method according to any one of claims 1 to 33 , wherein, following eltoprazine administration, plasma concentration of the subject is in the range of 9 ng/ml to 17 ng/ml.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/542,286 US20180263975A1 (en) | 2015-01-13 | 2016-01-13 | Methods Of Treating Motor And Movement Disorders And Side Effects Thereof Associated with Parkinson's Disease Treatments |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562103036P | 2015-01-13 | 2015-01-13 | |
US15/542,286 US20180263975A1 (en) | 2015-01-13 | 2016-01-13 | Methods Of Treating Motor And Movement Disorders And Side Effects Thereof Associated with Parkinson's Disease Treatments |
PCT/US2016/013206 WO2016115223A1 (en) | 2015-01-13 | 2016-01-13 | Methods of treating motor and movement disorders and side effects thereof associated with parkinson's disease treatments |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180263975A1 true US20180263975A1 (en) | 2018-09-20 |
Family
ID=56406325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/542,286 Abandoned US20180263975A1 (en) | 2015-01-13 | 2016-01-13 | Methods Of Treating Motor And Movement Disorders And Side Effects Thereof Associated with Parkinson's Disease Treatments |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180263975A1 (en) |
EP (1) | EP3244892A4 (en) |
CA (1) | CA2973701A1 (en) |
HK (1) | HK1246687A1 (en) |
WO (1) | WO2016115223A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113453683A (en) * | 2018-12-20 | 2021-09-28 | 康特拉医药股份有限公司 | Treatment of movement disorders |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3030089C (en) | 2016-07-11 | 2024-04-23 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090298850A1 (en) * | 2008-05-30 | 2009-12-03 | Psychogenics, Inc. | Treatment for Neurological and Mental Disorders |
US20110288105A1 (en) * | 2008-12-05 | 2011-11-24 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of l-dopa-induced dyskinesia |
US20130033139A1 (en) * | 2011-08-01 | 2013-02-07 | Garlock Sealing Technologies, Llc | Method of Securing a Sealing Device to a Housing with a Limited Bore Diameter |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6417210B1 (en) * | 1998-01-09 | 2002-07-09 | Mor-Research Applications Ltd. | Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa |
US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
EP2317996A1 (en) * | 2008-06-24 | 2011-05-11 | Anders Björklund | Eltoprazine for suppression of l-dopa induced dyskinesias |
-
2016
- 2016-01-13 WO PCT/US2016/013206 patent/WO2016115223A1/en active Application Filing
- 2016-01-13 CA CA2973701A patent/CA2973701A1/en not_active Abandoned
- 2016-01-13 EP EP16737796.9A patent/EP3244892A4/en not_active Withdrawn
- 2016-01-13 US US15/542,286 patent/US20180263975A1/en not_active Abandoned
-
2018
- 2018-05-17 HK HK18106452.8A patent/HK1246687A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090298850A1 (en) * | 2008-05-30 | 2009-12-03 | Psychogenics, Inc. | Treatment for Neurological and Mental Disorders |
US20110288105A1 (en) * | 2008-12-05 | 2011-11-24 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of l-dopa-induced dyskinesia |
US20130033139A1 (en) * | 2011-08-01 | 2013-02-07 | Garlock Sealing Technologies, Llc | Method of Securing a Sealing Device to a Housing with a Limited Bore Diameter |
Non-Patent Citations (1)
Title |
---|
Standard Medication Administration Times, pages 1-6. (Year: 2014) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113453683A (en) * | 2018-12-20 | 2021-09-28 | 康特拉医药股份有限公司 | Treatment of movement disorders |
Also Published As
Publication number | Publication date |
---|---|
WO2016115223A1 (en) | 2016-07-21 |
CA2973701A1 (en) | 2016-07-21 |
HK1246687A1 (en) | 2018-09-14 |
EP3244892A4 (en) | 2018-09-19 |
EP3244892A1 (en) | 2017-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180250295A1 (en) | Treatment of Motor and Movement Disorder Side Effects Associated with Parkinson's Disease Treatments | |
US20210137852A1 (en) | Use of rasagiline for the treatment of restless legs syndrome | |
US20060173074A1 (en) | Treatment of restless legs syndrome | |
US20180263975A1 (en) | Methods Of Treating Motor And Movement Disorders And Side Effects Thereof Associated with Parkinson's Disease Treatments | |
US11166922B2 (en) | Method for treating hyperhidrosis with dexmecamylamine | |
JP6084931B2 (en) | Neramexane for the treatment or prevention of tinnitus associated with stress or acute hearing loss | |
US7915262B2 (en) | Combination preparations comprising SLV308 and a dopamine agonist | |
EP2035002A1 (en) | Combination preparations comprising slv308 and a l-dopa | |
JP2023504876A (en) | Pharmaceutical composition, kit and its application | |
US20130150375A1 (en) | GEPIRONE-ER TREATMENT OF MAJOR DEPRESSION IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) | |
US20050032784A1 (en) | Combination drug therapy for treating hypertension | |
MX2008004197A (en) | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |